var title_f19_15_19696="Bladder exstrophy";
var content_f19_15_19696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exstrophy in a male newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19696=[""].join("\n");
var outline_f19_15_19696=null;
var title_f19_15_19697="Optic disc Frisen grade 3";
var content_f19_15_19697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade 3 showing obscuration of a major vessel as it leaves the optic disc (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19697=[""].join("\n");
var outline_f19_15_19697=null;
var title_f19_15_19698="Captive bead ring";
var content_f19_15_19698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Captive bead ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of R Michelle Schmidt, MD and Myrna L Armstrong, EdD, RN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19698=[""].join("\n");
var outline_f19_15_19698=null;
var title_f19_15_19699="Stye - lower lid";
var content_f19_15_19699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Stye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An abscess is present below the lash line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19699=[""].join("\n");
var outline_f19_15_19699=null;
var title_f19_15_19700="Alclometasone: Drug information";
var content_f19_15_19700=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alclometasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/51/38707?source=see_link\">",
"    see \"Alclometasone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/55/28531?source=see_link\">",
"    see \"Alclometasone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aclovate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive dermatoses: Topical: Apply a thin film to the affected area 2-3 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F131069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/55/28531?source=see_link\">",
"      see \"Alclometasone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive dermatoses: Topical: Children &ge;1 year: Apply thin film to affected area 2-3 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Do not use for &gt;3 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as dipropionate: 0.05% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclovate&reg;: 0.05% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as dipropionate: 0.05% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclovate&reg;: 0.05% (15 g [DSC], 60 g [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Apply a thin film to clean, dry skin and rub in gently. Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area (including diapered area). Should not be used in the presence of open or weeping lesions. Wash hands thoroughly before and after use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inflammation of corticosteroid-responsive dermatosis (low to medium potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aclovate&reg; may be confused with Accolate&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cloderm: Brand name for alclometasone [Indonesia], but also brand name for clobetasol [China, India, Malaysia, Singapore, Thailand]; clocortolone [U.S., Canada]; clotrimazole [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic:  Acne, allergic dermatitis, hypopigmentation, perioral dermatitis, skin atrophy, striae, miliaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: HPA axis suppression, Cushing's syndrome, growth retardation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Dryness (2%), irritation (2%), papular rash (2%), burning (1% to 2%), erythema (1% to 2%), itching (1% to 2%), folliculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alclometasone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;1 year of age. Not for the treatment of diaper dermatitis. Safety and efficacy for use &gt;3 weeks has not been established. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Avoid contact with eyes. Generally not for routine use on the face, underarms, or groin area (including diapered area).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4804818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some corticosteroids were found to be teratogenic following topical application in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13258058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13258059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of  alclometasone are absorbed following topical administration to produce detectable amounts in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F131060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Aclovate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $52.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Alclometasone Dipropionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (45 g): $39.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Alclometasone Dipropionate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (45 g): $29.82",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13258424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If HPA axis suppression is suspected, evaluate patient using the following tests:  ACTH stimulation test, AM plasma cortisol test, and urinary free cortisol test",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acloderm (CZ, RU);",
"     </li>",
"     <li>",
"      Aclosone (NL);",
"     </li>",
"     <li>",
"      Almeta (JP);",
"     </li>",
"     <li>",
"      Cloderm (ID);",
"     </li>",
"     <li>",
"      Delonal (DE);",
"     </li>",
"     <li>",
"      Demiderm (VE);",
"     </li>",
"     <li>",
"      Legederm (IT);",
"     </li>",
"     <li>",
"      Logoderm (NZ);",
"     </li>",
"     <li>",
"      Lomesone (GR);",
"     </li>",
"     <li>",
"      Miloderme (PT);",
"     </li>",
"     <li>",
"      Modraderm (BE);",
"     </li>",
"     <li>",
"      Modrasone (GB, IE);",
"     </li>",
"     <li>",
"      Perderm (AE, BH, CY, EG, HK, HN, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4804819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Topical: ~3% absorbed systemically after 8 hours when applied to intact skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19700/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19700/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9399 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19700=[""].join("\n");
var outline_f19_15_19700=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131062\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131074\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131063\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131069\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131064\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131054\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131040\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131057\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131055\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131081\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131072\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131059\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131044\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298696\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131049\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131051\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4804818\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13258058\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13258059\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131060\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13258424\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038319\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131043\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4804819\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/51/38707?source=related_link\">",
"      Alclometasone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/55/28531?source=related_link\">",
"      Alclometasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_15_19701="Nailfold capillaroscopy - Raynaud phenomenon";
var content_f19_15_19701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nailfold capillaroscopy - Raynaud phenomenon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 479px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) The normal nailfold capillaroscopic pattern, showing regular disposition of the capillary loops along the nail bed (original magnification 200x, M. Cutolo). Panel B) A decreased number of loops should be considered highly specific for secondary Raynaud's phenomenon and induce 'desertification' of the nail bed (original magnification 200x, M. Cutolo).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cutolo, M, Pizzorni, C, Secchi, ME, Sulli, A. Capillaroscopy. Best Pract Res Clin Rheumatol 2008; 22:1093. Copyright &copy; 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19701=[""].join("\n");
var outline_f19_15_19701=null;
var title_f19_15_19702="Sodium phosphate: Patient drug information";
var content_f19_15_19702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium phosphate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     see \"Sodium phosphate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"     see \"Sodium phosphate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Enema Extra&reg; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Enema [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Enema [OTC];",
"     </li>",
"     <li>",
"      LaCrosse Complete [OTC];",
"     </li>",
"     <li>",
"      OsmoPrep&reg;;",
"     </li>",
"     <li>",
"      Visicol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet Enema&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Oral solution or tablets taken before a colon exam may raise your chance of long-lasting kidney disease. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691271",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used as a laxative to clean out the colon before an exam.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium phosphates or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A large colon or bowel block.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high phosphate levels, low calcium levels, or high sodium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A large colon, fluid in the belly, GI (gastrointestinal) block, very bad kidney disease, or a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs right after this tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drugs taken after using the tablets may not get into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids that have magnesium or aluminum or sucralfate with the oral drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have had a recent heart attack (within 3 months) or heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Parts of the tablet in the stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the kidneys may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If liquid drug does not come out after rectal use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705337",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bowel exams:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink clear liquids for 12 hours before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Hard stools (constipation):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix dose with 1 cup of cool water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694758",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more doses for at least 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use enema rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696489",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug before an exam, take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11050 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-73EC6B31EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19702=[""].join("\n");
var outline_f19_15_19702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030170\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030172\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030171\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030176\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030177\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030179\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030174\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030175\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030180\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030181\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=related_link\">",
"      Sodium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=related_link\">",
"      Sodium phosphate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_15_19703="Ethanol (topical and injection): Pediatric drug information";
var content_f19_15_19703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethanol (topical and injection): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/50/4904?source=see_link\">",
"    see \"Ethanol (topical and injection): Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epi-Clenz&trade; [OTC];",
"     </li>",
"     <li>",
"      Gel-Stat&trade; [OTC];",
"     </li>",
"     <li>",
"      GelRite&trade; [OTC];",
"     </li>",
"     <li>",
"      Isagel&reg; [OTC];",
"     </li>",
"     <li>",
"      Lavacol&reg; [OTC];",
"     </li>",
"     <li>",
"      Prevacare&reg; [OTC];",
"     </li>",
"     <li>",
"      Protection Plus&reg; [OTC];",
"     </li>",
"     <li>",
"      Purell&reg; 2 in 1 [OTC];",
"     </li>",
"     <li>",
"      Purell&reg; Lasting Care [OTC];",
"     </li>",
"     <li>",
"      Purell&reg; Moisture Therapy [OTC];",
"     </li>",
"     <li>",
"      Purell&reg; with Aloe [OTC];",
"     </li>",
"     <li>",
"      Purell&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Biobase-G&trade;;",
"     </li>",
"     <li>",
"      Biobase&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-infective Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Ethylene Glycol Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Methanol Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Fat Occlusion (Central Venous Catheter), Treatment Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neurolytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/50/4904?source=see_link\">",
"      see \"Ethanol (topical and injection): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Absolute ethanol/ethyl alcohol (EtOH):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of methanol or ethylene glycol ingestion: Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Loading dose (LD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.8-1 mL/kg of 95% EtOH or 2 mL/kg of 40% EtOH (equivalent to 80 proof undiluted liquor) or 1.8 mL/kg of 43% EtOH (equivalent to 86 proof undiluted liquor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 8-10 mL/kg of 10% EtOH solution, not to exceed 200 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Modified loading dose (if ingestion consists of both EtOH",
"     <b>",
"      and",
"     </b>",
"     methanol or ethylene glycol): The loading dose is reduced in a proportional manner related to the measured EtOH blood level by multiplying the calculated loading dose described above by the following factor:",
"    </p>",
"    (",
"    <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/14/26861\">",
"     See Loading dose formula",
"    </a>",
"    )",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance dose: See table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"left\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Non-Drinker",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Average Drinker",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Chronic Drinker",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Continue therapy until methanol or ethylene glycol blood level &lt;10 mg/dL",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         EtOH dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         by weight",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         66 mg/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         110 mg/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         154 mg/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Oral: 43% EtOH (34 g EtOH/dL; 86 proof undiluted liquor)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.3 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.46 mL/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Oral: 95% EtOH (75 g EtOH/dL)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.1 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.15 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2 mL/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         I.V.: 10% EtOH (7.9 g EtOH/dL)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.83 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.4 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 mL/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hemodialysis:",
"     </b>",
"     See table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Maintenance Dose Adjustment of Dialysis",
"      <sup>",
"       1",
"      </sup>",
"      :",
"     </caption>",
"     <col align=\"left\" width=\"250\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Non-Drinker",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Chronic Drinker",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Due to considerable variability of EtOH clearance between patients, adjust dosage as needed based upon serum EtOH levels.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         EtOH dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         by weight",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         169 mg/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         257 mg/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Oral: 43% EtOH (34 g EtOH/dL)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.77 mL/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         I.V.: 10% EtOH (7.9 g EtOH/dL)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.13 mL/kg/h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.26 mL/kg/h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Treatment of fat occlusion of central venous catheters: Children and Adults: I.V. (see institutional-based protocol for catheter clearance assessment, the following assessment is a general methodology): Up to 3 mL of 70% ethanol (maximum: 0.55 mL/kg); instill a volume equal to the internal volume of the catheter; may repeat if patency not restored after 30- minute dwell time; if dose repeated, reassess after 4-hour dwell time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dehydrated alcohol injection:",
"     </b>",
"     Therapeutic neurolysis (nerve or ganglion block): Adults: Intraneural: Dosage variable depending upon the site of injection, eg, trigeminal neuralgia: 0.05-0.5 mL as a single injection per interspace vs subarachnoid injection: 0.5-1 mL as a single injection per interspace; single doses &gt;1.5 mL are seldom required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Liquid denatured alcohol:",
"     </b>",
"     Topical: Children and Adults: Apply as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical [instant hand sanitizer]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epi-Clenz&trade;: 70% (240 mL) [contains aloe, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [foam/instant hand sanitizer]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epi-Clenz&trade;: 70% (480 mL) [contains aloe, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [instant hand sanitizer]: 62% (1.5 mL, 118 mL, 354 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epi-Clenz&trade;: 70% (45 mL, 120 mL, 480 mL) [contains aloe, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Stat&trade;: 62% (120 mL, 480 mL) [contains aloe, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GelRite&trade;: 67% (120 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GelRite&trade;: 67% (800 mL) [contains vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isagel&reg;: 60% (59 mL, 118 mL, 621 mL, 800 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacare&reg;: 60% (120 mL, 240 mL, 960 mL, 1200 mL, 1500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg;: 62% (60 mL, 360 mL, 1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg;: 62% (15 mL, 30 mL, 59 mL, 60 mL, 120 mL, 236 mL, 240 mL, 250 mL, 360 mL, 500 mL, 800 mL, 1000 mL, 2000 mL) [contains moisturizers, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg;: 62% (15 mL, 60 mL, 360 mL, 800 mL, 1000 mL) [contains vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg; Lasting Care: 62% (120 mL, 240 mL, 1000 mL) [contains moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg; Moisture Therapy: 62% (75 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg; with Aloe: 62% (60 mL, 120 mL, 354 mL, 800 mL, 1000 mL, 2000 mL) [contains aloe, moisturizers, tartrazine, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg; with Aloe: 62% (15 mL, 59 mL, 236 mL) [contains aloe, tartrazine, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [dehydrated, preservative free]: 98% (1 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [denatured]: 70% (480 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [denatured/rubbing alcohol]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lavacol&reg;: 70% (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [instant hand sanitizer]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg; 2 in 1: 62% (60 mL, 360 mL, 1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical [instant hand sanitizer/towelette]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isagel&reg;: 60% (50s, 300s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg;: 62% (24s) [contains aloe, moisturizers, tartrazine, vitamin A, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purell&reg;: 62% (35s, 175s) [contains moisturizers, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [instant hand sanitizer]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protection Plus&reg;: 62% (800 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Dilute ethanol in 6 ounces orange juice and give over 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Not for SubQ administration; I.V.: Dilute absolute alcohol for I.V. administration to a final concentration of 5% to 10% v/v in D",
"     <sub>",
"      5",
"     </sub>",
"     W or D",
"     <sub>",
"      10",
"     </sub>",
"     W; infuse loading dose plus 1 hour of maintenance dosage over 60 minutes; for treatment of occluded central venous catheter, a 70% dilution of ethanol may be made by adding 0.8 mL SWI to 2 mL 98% ethanol; instill with a volume equal to the internal volume of the catheter; assess patency at 30 minutes (or per institutional protocol); may repeat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intraneural: Separate needles should be used for each of multiple injections or sites to prevent residual alcohol deposition at sites not intended for tissue destruction; inject slowly after determining proper placement of needle; since dehydrated alcohol is hypobaric when compared with spinal fluid, proper positioning of the patient is essential to control localization of injections into the subarachnoid space",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not use unless solution is clear and container is intact",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote for the treatment of methanol and ethylene glycol intoxication; neurolysis of nerves or ganglia for the relief of intractable, chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (dehydrated alcohol injection); topical anti-infective; treatment of occluded central venous catheters due to lipid deposition from fat emulsion infusion (particularly 3-in-1 admixture)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ethanol may be confused with Ethyol&reg;, Ethamolin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F131138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, CNS depression, coma, disorientation, drowsiness, encephalopathy, headache, sedation, seizure (rare), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastric irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Nerve and tissue destruction, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Intoxication",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethyl alcohol; seizure disorder and diabetic coma; subarachnoid injection of dehydrated alcohol in patients receiving anticoagulants",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in diabetics (ethyl alcohol decreases blood sugar), hepatic impairment, patients with gout, shock, following cranial surgery, and in anticipated postpartum hemorrhage; monitor blood glucose closely, particularly in children as treatment of ingestions is associated with hypoglycemia; avoid extravasation during I.V. administration; ethyl alcohol passes freely into breast milk at a level approximately equivalent to maternal serum level; effects on the infant are insignificant until maternal blood level reaches 300 mg/dL; minimize dermal exposure of ethyl alcohol in infants as significant systemic absorption and toxicity can occur",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethyl alcohol is a flammable liquid and should be kept cool and away from any heat source; proper positioning of the patient for neurolytic administration is essential to control localization of the injection of dehydrated alcohol (which is hypobaric) into the subarachnoid space; avoid extravasation; not for SubQ administration; do not administer simultaneously with blood due to the possibility of pseudoagglutination or hemolysis; may potentiate severe hypoprothrombic bleeding; clinical evaluation and periodic lab determinations, including serum ethyl alcohol levels, are necessary to monitor effectiveness, changes in electrolyte concentrations, and acid-base balance (when used as an antidote)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: Alcohol (Ethyl) may enhance the teratogenic effect of Acitretin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): Alcohol (Ethyl) may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: Alcohol (Ethyl) may enhance the hepatotoxic effect of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Bromocriptine. Bromocriptine may enhance the adverse/toxic effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Alcohol (Ethyl) may enhance the CNS depressant effect of Buprenorphine.  Management: Advise patients receiving buprenorphine about the increased risk of CNS depression if they consume alcohol.  Consider alternatives to buprenorphine for opioid addiction treatment in patients who are dependent on alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Alcohol (Ethyl) may enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment.  Management: Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CefoTEtan: May enhance the adverse/toxic effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: Alcohol (Ethyl) may enhance the CNS depressant effect of CloBAZam. Alcohol (Ethyl) may increase the serum concentration of CloBAZam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Alcohol (Ethyl) may enhance the neurotoxic effect of CycloSERINE. Specifically, the risk for seizures may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethionamide: Alcohol (Ethyl) may enhance the adverse/toxic effect of Ethionamide. Specifically, there may be a risk for a psychotic episode/reaction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Alcohol (Ethyl) may enhance the CNS depressant effect of Fosphenytoin. Alcohol (Ethyl) may decrease the serum concentration of Fosphenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin. This may be particularly applicable with acute, heavy alcohol consumption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin Enacarbil: Alcohol (Ethyl) may enhance the CNS depressant effect of Gabapentin Enacarbil. Alcohol (Ethyl) may increase the absorption of Gabapentin Enacarbil. Specifically, the rate of absorption may be enhanced, as alcohol may speed the release of drug from the extended-release tablet.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ISOtretinoin: Alcohol (Ethyl) may enhance the adverse/toxic effect of ISOtretinoin. Specifically, the risk for elevated triglyceride concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: Alcohol (Ethyl) may enhance the hepatotoxic effect of Lomitapide.  Management: Advise patients to limit alcohol consumption to 1 drink per day while receiving lomitapide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Alcohol (Ethyl) may enhance the CNS depressant effect of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: Alcohol (Ethyl) may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Alcohol (Ethyl) may enhance the hepatotoxic effect of Mipomersen.  Management: Patients being treated with mipomersen should limit their consumption of alcohol to a maximum of 1 drink (or equivalent) per day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: Alcohol (Ethyl) may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: Alcohol (Ethyl) may increase the serum concentration of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: Alcohol (Ethyl) may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of Alcohol (Ethyl). Alcohol may also worsen the negative behavioral and psychiatric effects of Perampanel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phentermine: Alcohol (Ethyl) may enhance the adverse/toxic effect of Phentermine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Alcohol (Ethyl) may enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute, heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic, heavy alcohol consumption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Alcohol (Ethyl) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: Alcohol (Ethyl) may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Alcohol (Ethyl) may decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Alcohol (Ethyl) may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: Alcohol (Ethyl) may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.  Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: Alcohol (Ethyl) may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran.  Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Alcohol (Ethyl) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: May enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the dermatologic adverse effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Alcohol (Ethyl) may enhance the CNS depressant effect of Tapentadol. Alcohol (Ethyl) may increase the serum concentration of Tapentadol. Specifically, alcohol may increase the maximum serum concentrations when used with extended-release tapentadol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Alcohol (Ethyl) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tinidazole: May enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: Alcohol (Ethyl) may enhance the hepatotoxic effect of Trabectedin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: Alcohol (Ethyl) may enhance the CNS depressant effect of Trospium. Alcohol (Ethyl) may increase the serum concentration of Trospium. Specifically, alcohol may increase the peak (maximum) serum concentration of trospium when consumed within 2 hours of taking extended-release trospium.  Management: Avoid consuming any alcohol within 2 hours of taking a dose of trospium XR.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Alcohol (Ethyl) may enhance the adverse/toxic effect of Varenicline. Specifically, the risk for neuropsychiatric adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (injection) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with alcohol injection. Ethanol crosses the placenta, enters the fetal circulation, and has teratogenic effects in humans. The following withdrawal symptoms have been noted in the neonate following maternal ethanol consumption during pregnancy: Crying, hyperactivity, irritability, poor suck, tremors, seizures, poor sleeping pattern, hyperphagia, and diaphoresis. Fetal alcohol syndrome (FAS) is a term referring to a combination of physical, behavioral, and cognitive abnormalities resulting from ethanol exposure during fetal development. Since a &ldquo;safe&rdquo; amount of ethanol consumption during pregnancy has not been determined, the AAP recommends those women who are pregnant or planning a pregnancy refrain from all ethanol intake. When used as an antidote during the second or third trimester, FAS is not likely to occur due to the short treatment period; use during the first trimester is controversial.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidotal therapy: Blood ethanol levels (at the end of the loading dose, every hour until stabilized, and then every 8-12 hours thereafter); blood glucose, electrolytes (including serum magnesium), arterial pH, blood gases, methanol or ethylene glycol blood levels, heart rate, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Symptoms associated with serum ethanol levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nausea and vomiting: Serum level &gt;100 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coma: Serum level &gt;300 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antidote for methanol/ethylene glycol: Goal range: Blood ethanol level: 100-150 mg/dL (22-32 mmol/liter)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits the oxidation of methanol and ethylene oxide by alcohol dehydrogenase to their more toxic metabolites; as a neurolytic, ethyl alcohol produces injury to tissue cells by producing dehydration and precipitation of protoplasm; when injected in close proximity to nerve cells, it produces neuritis and nerve degeneration",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6-0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to acetaldehyde or acetate by alcohol dehydrogenase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clearance: Adults: 15-20 mg/dL/hour (range: 10-34 mg/dL/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis clearance: 300-400 mL/minute with an ethanol removal rate of 280 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eighty-proof spirits contain 40% ethanol; 86 proof spirits contain 43% ethanol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barceloux DG, Bond GR, Krenzelok EP, et al, &ldquo;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2002, 40(4):415-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19703/abstract-text/12216995/pubmed\" id=\"12216995\" target=\"_blank\">",
"        12216995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chernow B, ed, &ldquo;Poisoning&rdquo;,",
"      <i>",
"       Essentials of Critical Care Pharmacology",
"      </i>",
"      , 2nd ed, Baltimore: Williams &amp; Wilkins, 1994, 501-29.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pennington CR and Pithie AD, &ldquo;Ethanol Lock in the Management of Catheter Occlusion,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 1987, 11(5):507-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19703/abstract-text/3116300/pubmed\" id=\"3116300\" target=\"_blank\">",
"        3116300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Poisoning and Drug Overdose",
"      </i>",
"      , 2nd ed, Olson KR, ed, Norwalk, Connecticut: Appleton and Lange, 1994, 339-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Werlin SL, Lausten T, Jessens, et al, &ldquo;Treatment of Central Venous Catheter Occlusions With Ethanol and Hydrochloric Acid,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 1995, 19(5):416-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19703/abstract-text/8577023/pubmed\" id=\"8577023\" target=\"_blank\">",
"        8577023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13289 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19703=[""].join("\n");
var outline_f19_15_19703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131116\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131117\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056328\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056321\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131096\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131086\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056332\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056324\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056331\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131139\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131138\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056335\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056320\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056319\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298697\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217619\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131093\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131105\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056327\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056330\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056334\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056326\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056336\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13289\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13289|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/14/26861\" title=\"Loading dose\">",
"      Loading dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13289|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/50/4904?source=related_link\">",
"      Ethanol (topical and injection): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_15_19704="Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides";
var content_f19_15_19704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/15/19704/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19704/contributors\">",
"     Daniel M Musher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/15/19704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19704/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/15/19704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19704/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/15/19704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus pneumoniae (pneumococcus), the most common cause of bacterial respiratory tract infections in children and adults, was susceptible to virtually all antibiotics used in treating such infections until outbreaks of infection due to antibiotic-resistant pneumococci were recognized in South Africa in the late 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although the responsible organisms were called penicillin-resistant pneumococci (PRP), they had acquired genetic material that encoded resistance both to penicillin and to other commonly used antibiotics.",
"   </p>",
"   <p>",
"    In the ensuing decades, resistance of pneumococci to several clinically relevant classes of antibiotics has evolved from an ominous medical curiosity to a worldwide health problem.",
"   </p>",
"   <p>",
"    Macrolides, azalides, lincosamines, and ketolides are related drugs that inhibit protein synthesis at the same site in the bacterial ribosome and are generally active against the same microorganisms. Macrolides, azalides, and ketolides are (or, at least, used to be) generally active against S. pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella species, Chlamydia pneumoniae, and Mycoplasma pneumoniae.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    , the only lincosamine currently in use, is effective against most pneumococci, but is not active against such pathogens as H. influenzae and M. catarrhalis.",
"   </p>",
"   <p>",
"    The mechanisms of action of, and resistance to macrolides, lincosamines, and ketolides, as well as clinical data on the outcome of therapy with these drugs for otitis, sinusitis, acute exacerbations of chronic bronchitis, pneumonia, and meningitis will be reviewed here. Resistance to the other classes of drugs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MACROLIDES AND AZALIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first of the macrolides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , is poorly tolerated. After oral administration, erythromycin causes gastrointestinal distress and is not reliably absorbed; it also frequently causes thrombophlebitis after intravenous administration. As a result, erythromycin has been largely replaced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , a newer macrolide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , an azalide. It is important to note that pneumococci that are resistant to erythromycin are also resistant to the newer macrolides and the azalides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms of action and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolides and azalides insert into a pocket of the 23S subunit of the 50S ribosome, specifically by attaching at domain V of the peptidyl transferase loop, thereby blocking protein assembly. In doing so, these drugs exert a bactericidal effect on S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The mechanism for killing pneumococci is complex; these drugs are generally regarded as bacteriostatic for other gram-positive pathogens such as Staphylococcus aureus, but they are bactericidal for pneumococci.",
"   </p>",
"   <p>",
"    Acquisition of genetic material, designated erm(B) or mef(A), leads to resistance to macrolides and azalides that may take one of two forms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      erm(B) encodes methylation of a base in domain V of the 23S rRNA (A2058). This methylation alters the site of attachment such that the macrolide no longer recognizes and binds to the ribosome. This lack of recognition creates high-level resistance (&gt;64",
"      <span class=\"nowrap\">",
"       mcg/mL);",
"      </span>",
"      thus, increasing the dose with a resulting increase in the concentration of the drug has little effect.",
"     </li>",
"     <li>",
"      mef(A) encodes an efflux pump that excludes macrolides. This resistance is at a lower level (usually &lt;16",
"      <span class=\"nowrap\">",
"       mcg/mL);",
"      </span>",
"      high antibiotic concentrations might be expected to overcome the pump, forcing enough antibiotic into the bacterium to exert an antibacterial effect.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      are more active against pneumococci than is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , and it has been thought that they might be effective in vivo. However, the level of resistance in mef(A)-containing strains has been rising [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/5\">",
"       5",
"      </a>",
"      ], and it seems increasingly likely that the observed resistance will be clinically meaningful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some resistant isolates have both erm(B) and mef(A). In a small percentage of isolates, other mutations induce resistance, for example, by causing other base substitutions in domain V or by altering protein sequences within or adjacent to the macrolide binding site, especially involving ribosomal proteins L4 and L22 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, approximately 30 to 35 percent of pneumococci in the United States are resistant to macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. For reasons that are unexplained, there is substantial regional variation, with resistance rates approaching 40 percent in the Southeast, yet remaining around 25 percent in the Southwest and Northwest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Resistance is attributable to mefA and ermB in approximately equal numbers of cases, with about 25 percent of isolates carrying both elements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/11\">",
"     11",
"    </a>",
"    ]. Although the introduction of the pneumococcal conjugate vaccine into the vaccine schedule for children in the United States in 2000 was anticipated to reduce resistance by leading to the elimination of resistant nasal carriage strains, this appears not to have been the case, since emerging &ldquo;replacement&rdquo; strains also have a high rate of resistance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The level of resistance among mef(A) strains has steadily increased in the past few years, presumably related to increased use of macrolides in the community. Thus, even those organisms that have had lower-level resistance in the past are becoming less likely to respond to treatment with macrolides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A higher proportion of pneumococci in Europe are macrolide-resistant, and erm(B) is responsible in the majority of phenotypically-resistant isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/13\">",
"     13",
"    </a>",
"    ]. Rates of resistance are lower in Canada than in the United States and higher in the Far East than in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The rates of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    resistance in Asia were 55 percent overall, 92 percent in Vietnam, and 70 percent in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the study from Japan, half of the isolates were highly resistant (MIC &ge;16",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    and resistance was most frequently identified among children younger than two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective cohort study of 3339 patients with invasive pneumococcal infection identified apparent risk factors for the acquisition of macrolide-resistant pneumococcal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/17\">",
"     17",
"    </a>",
"    ]. These include previous use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (odds ratio [OR] 9.9),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (OR 3.9), penicillin (OR 1.8), and TMP-SMX (OR 2.1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Resistance and the outcome of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although careful studies of otitis media have established a close relationship between the susceptibility of the infecting pneumococcus and the response to macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], the relationship among drug levels, inhibitory concentrations and clinical outcome has been less clear in cases of pneumonia. This is partially due to the fact that most studies of pneumonia focus on community-acquired pneumonia (CAP), in which an etiologic agent is often not established, and treatment regimens frequently combine a macrolide with a second antibiotic. Even when the use of macrolide monotherapy has been reported, the absence of an identified etiologic agent renders it difficult to interpret the results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/21\">",
"     21",
"    </a>",
"    ]. In evaluating reports of responses to therapy, it is essential to note the years during which patients were studied and the prevailing rate and level of resistance at those times, clearly a &ldquo;moving target&rdquo; in recent years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;One review summarized an extensive clinical experience by stating that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    cured nearly 95 percent of cases of otitis media when the organisms were susceptible to the drug but only 20 percent when they were not [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/20\">",
"     20",
"    </a>",
"    ]. In one study, for example, azithromycin (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on the first day and 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for four additional days) cured 23 of 25 children who had pneumococcal otitis media due to a fully susceptible organism (MIC &lt;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    compared to 3 of 8 children whose infecting organism was only susceptible to &gt;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/18\">",
"     18",
"    </a>",
"    ]. Unpublished data from the manufacturer of azithromycin suggest that 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as a single dose cures 85 percent of cases of pneumococcal otitis media, a finding which was consistent with the national rate (at the time the study was done) of 8 percent erm(B)-mediated resistance to macrolides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (500 mg daily for 3 to 5 days) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg twice daily for 10 to 14 days) effectively treats acute purulent sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A study from Croatia where, at the time, 25 percent of pneumococci were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    -resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/24\">",
"     24",
"    </a>",
"    ], showed a 95 percent cure rate by azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/25\">",
"     25",
"    </a>",
"    ]. These results might support the notion of a discrepancy between in vitro and in vivo resistance to this class of drugs, but a limitation of such studies is that most cases of sinusitis eventually resolve spontaneously, and the outcome of any study is determined by the severity of disease in the patients who are included. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the literature on macrolide resistance in pneumonia deals with groups of patients who are lumped together under the diagnosis of \"community-acquired pneumonia (CAP).\" A substantial proportion of these patients may be infected with S. pneumoniae, but many others may not be, and an uncertain, but probably large proportion of non-severe pneumonias may resolve without therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (500 mg on the first day followed by 250 mg daily for 4 more days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg twice daily for 10 days) effectively treat CAP in many outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/21,26-28\">",
"     21,26-28",
"    </a>",
"    ]. The 2007 Infectious Diseases Society of America and American Thoracic Society guidelines for the treatment of CAP use a 25 percent rate of high-level (&ge;16",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    macrolide resistance of pneumococcal isolates as the threshold at which this class should not be used for empiric monotherapy of CAP; the use of macrolide monotherapy for CAP should be limited to patients not requiring hospitalization and who have no significant comorbidities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of antibiotics within the last three months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the macrolide resistance threshold may need to be reassessed since a threshold that fails to consider low-level resistance may result in excess morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/30\">",
"     30",
"    </a>",
"    ]. Studies of macrolides for the treatment of CAP in outpatients are discussed in detail separately.",
"   </p>",
"   <p>",
"    Macrolide monotherapy is not recommended for the treatment of hospitalized patients with CAP. There is, however, a substantial body of literature suggesting that macrolides improve the outcome of therapy when they are included as part of combination therapy, generally when given together with a beta-lactam antibiotic. The use of macrolides as part of a combination regimen for the treatment of CAP in hospitalized patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H12#H12\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Macrolides versus other drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LINCOSAMINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is the only lincosamine in current use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanisms of action and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although structurally different from the macrolides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    acts at the same site in the ribosome, and its activity is blocked if the site is methylated; thus, pneumococci that have the erm(B) mutation are also resistant to clindamycin. However, this drug is not excluded from bacterial cells by the efflux pump, and mef(A) does not convey resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevalence of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of pneumococci in the United States are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    with regional variation, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment and response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon relatively limited clinical data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    provides effective therapy for pneumococcal pneumonia due to susceptible isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/31\">",
"     31",
"    </a>",
"    ], but it is not recommended for pneumonia of uncertain etiology because of the lack of efficacy against other common pathogens such as H. influenzae, M. catarrhalis, Legionella spp, and Mycoplasma pneumoniae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     KETOLIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ketolides are a new group of antibiotics.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    , one of the drugs in this class, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with sinusitis, AECB, and community-acquired pneumonia (CAP) in April 2004.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Warning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the possible side effects of severe hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/32\">",
"     32",
"    </a>",
"    ], visual disturbances, and serious exacerbation of myasthenia gravis, a federal advisory panel in December 2006 concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    should be a secondary alternative to other antimicrobial drugs for the treatment of mild-to-moderate pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H12#H12\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Warnings about telithromycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ketolides have two sites of action against S. pneumoniae. One is at domain V, as described above for the macrolides. However, the ketolides have a greater affinity than the macrolides for that site, and thus, have a much lower mean inhibitory concentration (MIC) for most organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/33\">",
"     33",
"    </a>",
"    ]. A second binding site is at domain II of the 23s ribosome, one that involves the same pocket of insertion, but to which macrolides do not bind [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, pneumococci that have erm(B) do not bind ketolides at domain V but still do bind at domain II, thereby explaining how ketolides remain active against these strains. In addition, ketolides have low affinity for the efflux pump protein and, therefore, isolates that contain mef(A) are not resistant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ketolides are active in vitro against both macrolide-susceptible and macrolide-resistant strains of S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. As an example, in a large study of pneumococci from Croatia where high-level macrolide resistance is prevalent, 99.8 percent of pneumococci were susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/35\">",
"     35",
"    </a>",
"    ]. Ketolides are also active against Legionella spp. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/36\">",
"     36",
"    </a>",
"    ], Chlamydia pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/37\">",
"     37",
"    </a>",
"    ] and Mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/36,38\">",
"     36,38",
"    </a>",
"    ] in vitro. Telithromycin-resistant pneumococci have already been isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/39\">",
"     39",
"    </a>",
"    ], however, and it is anticipated that the prevalence of such strains will increase in proportion to ketolide use.",
"   </p>",
"   <p>",
"    A survey of 1817 S. pneumoniae isolates collected during the winter of 2002-2003 from 44 United States medical centers found no resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    in treating otitis media, sinusitis, acute exacerbations of chronic bronchitis, and pneumonia have been published; further data are available through the FDA web site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/40\">",
"     40",
"    </a>",
"    ]. The drug has not been licensed for pediatric use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Acute sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five or 10 days of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    (800 mg once daily) were equally effective in treating acute maxillary sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/41\">",
"     41",
"    </a>",
"    ]. Clinical and bacteriologic responses (the latter based upon needle aspiration of the sinus) have been at least as good as those observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acute exacerbation of chronic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two large series of cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    achieved clinical and bacteriologic cures in a proportion of patients equal to or greater than that observed during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/44\">",
"     44",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from three randomized controlled double-blind trials demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    was equivalent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , or trovafloxacin in the treatment of CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of these trials, for example, 404 patients with CAP were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    (800 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (1 g three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/46\">",
"     46",
"    </a>",
"    ]. Telithromycin achieved a cure rate equivalent to that of high-dose amoxicillin (95 versus 90 percent). In bacteremic cases proven to be due to S. pneumoniae, 10 of 10 patients treated with telithromycin were cured compared to 7 of 9 with amoxicillin. In a second trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    with telithromycin, 19 of 19 bacteremic patients were successfully treated with telithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These exceptionally good outcomes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    are due in part to the exclusion of patients who were judged to have &ldquo;severe disease,&rdquo; as the mortality of pneumococcal pneumonia in adults is dependent upon the severity of the illness with mortality of 49 to 55 percent in severely ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19704/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The macrolides have long been important agents for treating community-acquired pneumonia (CAP), in large measure because of their excellent activity against pneumococci. However, increases in the proportion of macrolide-resistance pneumococci in multiple geographic regions during the past several years have reduced the utility of macrolide monotherapy for outpatients with CAP. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Macrolides and azalides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      is effective against pneumococci that have mef(A) resistance but not against those that have erm(B); the lack of activity against other respiratory pathogens (eg, H. influenzae) limits the utility of this drug in CAP unless pneumococci are known to be responsible. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lincosamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"       telithromycin",
"      </a>",
"      appears to offer substantial advantages over macrolides because of its efficacy against nearly all pneumococci, its use should be limited to a secondary alternative to other agents because of the potential for severe toxicity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Warning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/1\">",
"      Visalli MA, Jacobs MR, Appelbaum PC. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagn Microbiol Infect Dis 1997; 28:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/2\">",
"      Berry V, Thorburn CE, Knott SJ, Woodnutt G. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42:3193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/3\">",
"      Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/4\">",
"      Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/5\">",
"      Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/6\">",
"      Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/7\">",
"      Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/8\">",
"      Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/9\">",
"      Farrell DJ, Jenkins SG, Brown SD, et al. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005; 11:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/10\">",
"      Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/11\">",
"      Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/12\">",
"      Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/13\">",
"      P&eacute;rez-Trallero E, Fern&aacute;ndez-Mazarrasa C, Garc&iacute;a-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45:3334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/14\">",
"      Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/15\">",
"      Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/16\">",
"      Hotomi M, Billal DS, Shimada J, et al. Increase of macrolide-resistant Streptococcus pneumoniae-expressing mefE or ermB gene in the nasopharynx among children with otitis media. Laryngoscope 2005; 115:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/17\">",
"      Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/18\">",
"      Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/19\">",
"      Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/20\">",
"      Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J 2000; 19:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/21\">",
"      Kogan R, Mart&iacute;nez MA, Rubilar L, et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr Pulmonol 2003; 35:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/22\">",
"      Hayle R, Lingaas E, H&oslash;ivik HO, Odeg&aring;rd T. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1996; 15:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/23\">",
"      Murray JJ, Solomon E, McCluskey D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin Ther 2000; 22:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/24\">",
"      Tambic Andrasevic A, Tambic T, Kalenic S, et al. Surveillance for antimicrobial resistance in Croatia. Emerg Infect Dis 2002; 8:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/25\">",
"      Klapan I, Culig J, Oreskovi K, et al. Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/26\">",
"      Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/27\">",
"      Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/28\">",
"      Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/29\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/30\">",
"      Daneman N, Low DE, McGeer A, et al. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008; 46:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/31\">",
"      Cherubin CE, Magazine D, Hargrove C, et al. A comparative study of the treatment of presumed pneumococcal pneumonia: parenteral penicillin and clindamycin with continuation on oral therapy. Curr Ther Res Clin Exp 1975; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/32\">",
"      Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/33\">",
"      Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/34\">",
"      Xiong L, Shah S, Mauvais P, Mankin AS. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol Microbiol 1999; 31:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/35\">",
"      Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother 2002; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/36\">",
"      Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/37\">",
"      Miyashita N, Fukano H, Niki Y, Matsushima T. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001; 48:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/38\">",
"      Yamaguchi T, Hirakata Y, Izumikawa K, et al. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000; 44:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/39\">",
"      Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update. Clin Infect Dis 2004; 39 Suppl 3:S142.",
"     </a>",
"    </li>",
"    <li>",
"     Telithromycin FDA efficacy review NDA 21-144 available at the FDA website www.fda.gov/ohrms/dockets/ac/03/slides/3919S1_05_FDA-Alexander.ppt (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/41\">",
"      Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002; 48:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/42\">",
"      Buchanan P, Roos K, Tellier G, et al. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis. Int J Antimicrob Agents 2005; 25:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/43\">",
"      Ferguson BJ, Guzzetta RV, Spector SL, Hadley JA. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 131:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/44\">",
"      Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002; 96:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/45\">",
"      Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res 2003; 31:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/46\">",
"      Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002; 30:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/47\">",
"      Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003; 57:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/48\">",
"      Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/49\">",
"      Niederman MS, Chang JR, Stewart J, et al. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Curr Med Res Opin 2004; 20:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/50\">",
"      Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000; 79:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19704/abstract/51\">",
"      Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7033 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-7BCA055868-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19704=[""].join("\n");
var outline_f19_15_19704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MACROLIDES AND AZALIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms of action and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Resistance and the outcome of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Otitis media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LINCOSAMINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanisms of action and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevalence of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment and response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      KETOLIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Acute sinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acute exacerbation of chronic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_15_19705="Acetaminophen (paracetamol): Pediatric drug information";
var content_f19_15_19705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen (paracetamol): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"    see \"Acetaminophen (paracetamol): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"    see \"Acetaminophen (paracetamol): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F11391964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Acetaminophen: Transition of Pediatric Liquid Products to Standard Concentration",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2011",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Based on recommendations provided by the Food and Drug Administration (FDA), all over-the-counter (OTC) pediatric single-ingredient acetaminophen liquid products will transition to a single concentration of 160 mg/5 mL; the transition has already begun and will continue into 2012.  The concentration of acetaminophen infant drops (previously 80 mg/0.8 mL) will now be the same as children&rsquo;s acetaminophen products (160 mg/5 mL) and as a result, new dosing on a volume-per-weight (or volume-per-age) basis will apply. The recommended mg/kg dose is unaffected and continues to be 10-15 mg/kg/dose.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware that during this transition, acetaminophen infant drop products with both the new and old concentrations may be available on pharmacy shelves. Parents may continue to use either product, but should verify concentration and use according to labeled dosing directions. Healthcare professionals should verify product concentration prior to providing dosing information.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information can be found at  file://www.tylenolprofessional.com/index.html",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acephen&trade; [OTC];",
"     </li>",
"     <li>",
"      APAP 500 [OTC];",
"     </li>",
"     <li>",
"      Aspirin Free Anacin&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Cetafen&reg; Extra [OTC];",
"     </li>",
"     <li>",
"      Cetafen&reg; [OTC];",
"     </li>",
"     <li>",
"      Excedrin&reg; Tension Headache [OTC];",
"     </li>",
"     <li>",
"      Feverall&reg; [OTC];",
"     </li>",
"     <li>",
"      Infantaire [OTC];",
"     </li>",
"     <li>",
"      Little Fevers&trade; [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Arthritis Pain [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Infant's [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Junior Rapid Tabs [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; [OTC];",
"     </li>",
"     <li>",
"      Non-Aspirin Pain Reliever [OTC];",
"     </li>",
"     <li>",
"      Nortemp Children's [OTC];",
"     </li>",
"     <li>",
"      Ofirmev&trade;;",
"     </li>",
"     <li>",
"      Pain &amp; Fever Children's [OTC];",
"     </li>",
"     <li>",
"      Pain Eze [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Children's [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Infant's [OTC];",
"     </li>",
"     <li>",
"      Q-Pap [OTC];",
"     </li>",
"     <li>",
"      RapiMed&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      RapiMed&reg; Junior [OTC];",
"     </li>",
"     <li>",
"      Silapap Children's [OTC];",
"     </li>",
"     <li>",
"      Silapap Infant's [OTC];",
"     </li>",
"     <li>",
"      Triaminic&trade; Children's Fever Reducer Pain Reliever [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; 8 Hour [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Arthritis Pain Extended Relief [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Children's Meltaways [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Infant's Concentrated [OTC] [DSC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Jr. Meltaways [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; [OTC];",
"     </li>",
"     <li>",
"      Valorin Extra [OTC];",
"     </li>",
"     <li>",
"      Valorin [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abenol&reg;;",
"     </li>",
"     <li>",
"      Apo-Acetaminophen&reg;;",
"     </li>",
"     <li>",
"      Atasol&reg;;",
"     </li>",
"     <li>",
"      Novo-Gesic;",
"     </li>",
"     <li>",
"      Pediatrix;",
"     </li>",
"     <li>",
"      Tempra&reg;;",
"     </li>",
"     <li>",
"      Tylenol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipyretic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11426603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Limited data available; dose not established: Manufacturer&rsquo;s neonatal (PMA not specified) pharmacokinetic data suggest a maximum single dose: 7.5 mg/kg; maximum total daily dose: 37.5 mg/kg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Some experts do not recommend the use of I.V. acetaminophen in premature neonates &lt;32 weeks PMA until pharmacokinetic and pharmacodynamic studies have been conducted in this age group (van den Anker, 2011). Postmenstrual age (PMA) is the sum of GA (weeks) and PNA (weeks) (AAP, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose (Allegaert, 2007; Bartocci, 2007): 20 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose (Allegaert, 2007; Allegaert, 2011; Bartocci, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PMA 28-32 weeks: 10 mg/kg/dose every 12 hours; some suggest 7.5 mg/kg/dose every 8 hours; maximum daily dose: 22.5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PMA 33-36 weeks: 10 mg/kg/dose every 8 hours; some suggest 7.5-10 mg/kg/dose every 6 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PMA &ge;37 weeks: 10 mg/kg/dose every 6 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (Anand, 2001; Anand, 2002):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GA 28-32 weeks: 10-12 mg/kg/dose every 6-8 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GA 33-37 weeks or term neonates &lt;10 days: 10-15 mg/kg/dose every 6 hours; maximum daily dose: 60 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Term neonates &ge;10 days: 10-15 mg/kg/dose every 4-6 hours; maximum daily dose: 90 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal (Anand, 2001; Anand, 2002):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GA 28-32 weeks: 20 mg/kg/dose every 12 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GA 33-37 weeks or term neonates &lt;10 days: Loading dose: 30 mg/kg; then 15 mg/kg/dose every 8 hours; maximum daily dose: 60 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Term infants &ge;10 days: Loading dose: 30 mg/kg; then 20 mg/kg/dose every 6-8 hours; maximum daily dose: 90 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"      see \"Acetaminophen (paracetamol): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;2 years: 7.5-15 mg/kg/dose every 6 hours; maximum daily dose: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (Wilson-Smith, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-12 years: 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours; maximum single dose: 15 mg/kg; maximum daily dose: 75 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     not to exceed 3750 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 10-15 mg/kg/dose every 4-6 hours as needed; do",
"     <b>",
"      not",
"     </b>",
"     exceed 5 doses in 24 hours; alternatively, the following manufacturer recommended doses may be used. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Acetaminophen Dosing (Oral)",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (lbs)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Manufacturer's recommendations; use of weight to select dose is preferred; if weight is not available, then use age. Manufacturer&rsquo;s recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg. OTC labeling instructs consumer to consult with physician for dosing instructions in children under 2 years of age.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.7-5.3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6-11",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0-3 mo",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.4-8.1",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12-17",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4-11 mo",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.2-10.8",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         18-23",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1-2 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         120",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.9-16.3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         24-35",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         160",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16.4-21.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         36-47",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         21.8-27.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         320",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27.3-32.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9-10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32.7-43.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         72-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         480",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 10-20 mg/kg/dose every 4-6 hours as needed;",
"     <b>",
"      do",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"      exceed 5 doses in 24 hours",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Although the perioperative use of high-dose rectal acetaminophen (eg, 25-45 mg/kg/dose) has been investigated in several studies, its routine use remains controversial; optimal doses and dosing frequency to ensure efficacy and safety have not yet been established; further studies are needed (Buck, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day. No dose adjustment required when converting between different acetaminophen formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;50 kg: 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours; maximum single dose: 750 mg/dose; maximum daily dose: 75 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (&le;3750 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;50 kg: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg/dose; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release:",
"     <b>",
"      Note:",
"     </b>",
"     Actual OTC dosing recommendations may vary by product and/or manufacturer: 325-650 mg every 4-6 hours or 1000 mg 3-4 times/day; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: 1300 mg every 8 hours; maximum daily dose: 3900 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 325-650 mg every 4-6 hours or 1000 mg 3-4 times/day; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use with caution; consider decreasing daily dose and extending dosing interval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermittent hemodialysis or peritoneal dialysis: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CRRT: No adjustments necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermittent hemodialysis or peritoneal dialysis: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CRRT: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment/comments in hepatic impairment:",
"     </b>",
"     Use with caution. Limited, low-dose therapy is usually well-tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4000 mg/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetafen&reg; Extra: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain Eze: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Arthritis Pain: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; 8 Hour: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Arthritis Pain Extended Relief: 650 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Captab, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 160 mg/5 mL (118 mL, 480 mL) [ethanol free; contains benzoic acid, propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, rapid release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Geltab, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin&reg; Tension Headache: 500 mg [contains caffeine 65 mg/geltab]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ofirmev&trade;: 10 mg/mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 160 mg/5 mL (120 mL, 473 mL); 500 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     APAP 500: 500 mg/5 mL (237 mL) [ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Extra Strength: 500 mg/5 mL (237 mL) [contains propylene glycol, sodium 9 mg/15 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL, 473 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silapap Children's: 160 mg/5 mL (118 mL, 237 mL, 473 mL) [ethanol free, sugar free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg/15 mL (240 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 160 mg/5 mL (5 mL, 10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain &amp; Fever Children's: 160 mg/5 mL (118 mL, 473 mL) [ethanol free, sugar free; contains propylene glycol, sodium 1 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]: 80 mg/0.8 mL (15 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infantaire: 80 mg/0.8 mL (15 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Fevers&trade;: 80 mg/mL (30 mL) [dye free, ethanol free, gluten free; contains propylene glycol, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg;: 80 mg/0.8 mL (15 mL) [fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Infant's: 80 mg/0.8 mL (15 mL) [ethanol free; contains propylene glycol; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silapap Infant's: 80 mg/0.8 mL (15 mL, 30 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 120 mg (12s); 325 mg (12s); 650 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acephen&trade;: 120 mg (12s, 50s, 100s); 325 mg (6s, 12s, 50s, 100s); 650 mg (12s, 50s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feverall&reg;: 80 mg (6s, 50s); 120 mg (6s, 50s); 325 mg (6s, 50s); 650 mg (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 160 mg/5 mL (5 mL, 10.15 mL, 20.3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Infant's: 160 mg/5 mL (59 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nortemp Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium benzoate; cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pain &amp; Fever Children's: 160 mg/5 mL (60 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (60 mL, 120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's: 160 mg/5 mL (120 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Infant's: 80 mg/0.8 mL (15 mL, 30 mL) [ethanol free; contains propylene glycol, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Infant's Concentrated: 80 mg/0.8 mL (30 mL [DSC]) [dye free; contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Infant's Concentrated: 80 mg/0.8 mL (15 mL [DSC], 30 mL [DSC]) [ethanol free; contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Infant's Concentrated: 80 mg/0.8 mL (15 mL [DSC], 30 mL [DSC]) [ethanol free; contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&trade; Children's Fever Reducer Pain Reliever: 160 mg/5 mL (118 mL) [contains benzoic acid, sodium 6 mg/5 mL; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&trade; Children's Fever Reducer Pain Reliever: 160 mg/5 mL (118 mL) [contains sodium 5 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 325 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aspirin Free Anacin&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetafen&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Non-Aspirin Pain Reliever: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap: 325 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Pap Extra Strength: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg;: 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Extra Strength: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valorin: 325 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valorin Extra: 500 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 80 mg [fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 80 mg, 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 80 mg [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Children's: 80 mg [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mapap&reg; Junior Rapid Tabs: 160 mg [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Children's: 80 mg [gluten free, sugar free; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Children's: 80 mg [gluten free, sugar free; wild grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Junior: 160 mg [gluten free, sugar free; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RapiMed&reg; Junior: 160 mg [gluten free, sugar free; wild grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's Meltaways: 80 mg [scored; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Children's Meltaways: 80 mg [scored; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Jr. Meltaways: 160 mg [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; Jr. Meltaways: 160 mg [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release products; injectable formulation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: For I.V. infusion only. May administer undiluted over 15 minutes. Use within 6 hours of opening vial or transferring to another container. Discard any unused portion; single-use vials only. pH: 5.5; osmolarity: 290 mOsmol/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For doses &lt;1000 mg (&lt;50 kg): Withdraw appropriate dose from vial and place into separate empty, sterile container prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For doses &ge;1000 mg (&ge;50 kg): Insert vented I.V. set through vial stopper.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food to decrease GI upset; shake drops and suspension well before use; do not crush or chew extended release products",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11385126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Buprenorphine, butorphanol, cimetidine, dexamethasone sodium phosphate, diphenhydramine, dolasetron, droperidol, fentanyl, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ketorolac, lidocaine, lorazepam, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, midazolam, morphine, nalbuphine, ondansetron, potassium chloride, prochlorperazine, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11402271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     See individual product literature for detailed temperature information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store intact vials at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not refrigerate or freeze. Use within 6 hours of opening vial or transferring to another container. Incompatible with chlorpromazine and diazepam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral formulations: Store at controlled room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suppositories: Store at &lt;27&deg;C (80&deg;F). Do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (immediate release) and rectal formulations: Treatment of mild-to-moderate pain and fever (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (extended release): Treatment of mild to moderate pain and fever (see product specifics: FDA approved in ages &ge;12  or 18 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral formulation: Treatment of mild to moderate pain and fever; treatment of moderate to severe pain when combined with opioid analgesia (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acephen&reg; may be confused with AcipHex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FeverALL&reg; may be confused with Fiberall&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Triaminic&trade; Children's Fever Reducer Pain Reliever may be confused with Triaminic&reg; cough and cold products",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylenol&reg; may be confused with atenolol, timolol, Tylenol&reg; PM, Tylox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Infant concentration change: The new infant acetaminophen concentration (160 mg/5 mL) is available. All children&rsquo;s liquid acetaminophen products will now be the same 160 mg/5 mL concentration. However, the former infant acetaminophen concentration (80 mg/0.8 mL) may still be available in some pharmacies until supplies run out. Check concentrations closely prior to administering or dispensing (November 2011).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Injection: Reports of 10-fold overdose errors using the parenteral product have occurred in the U.S. and Europe; calculation of doses in \"mg\" and subsequent administration of the dose in \"mL\" using the commercially available concentration of 10 mg/mL contributed to these errors. Expressing doses as mg",
"       <b>",
"        and",
"       </b>",
"       mL, as well as pharmacy preparation of doses,  may decrease error potential (Dart, 2012; ISMP, 2012).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depon [Greece] may be confused with Depen brand name for penicillamine [U.S.]; Depin brand name for  nifedipine [India]; Dipen brand name for diltiazem [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Duorol [Spain] may be confused with Diuril brand name for chlorothiazide [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paralen [Czech Republic] may be confused with Aralen brand name for chloroquine [U.S., Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F129374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral, Rectal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased bicarbonate, calcium, sodium; increased chloride, glucose, uric acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, blood dyscrasias (neutropenia, pancytopenia, leukopenia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Ammonia increased, analgesic nephropathy, nephrotoxicity with chronic overdose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema (peripheral), hypervolemia, hypo/hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, fatigue, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia, hypokalemia, hypomagnesemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Infusion site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms, pain in extremity, trismus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Atelectasis, breath sounds abnormal, dyspnea, hypoxia, pleural effusion, pulmonary edema, stridor, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      All formulations:",
"     </b>",
"     Rare but important or life-threatening: Anaphylaxis (rare), hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen or any component; severe hepatic impairment or severe active liver disease (Ofirmev&trade;)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with alcoholic liver disease, hepatic impairment (parenteral use is contraindicated in severe impairment), or active liver disease (parenteral use is contraindicated). Use with caution in patients with chronic malnutrition or severe renal impairment; use intravenous formulation with caution in patients with severe hypovolemia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Although several case reports of acetaminophen-associated hemolytic anemia have been reported in patients with G-6-PD deficiency, a direct cause and effect relationship has not been well established (concurrent illnesses such as fever or infection may precipitate hemolytic anemia in patients with G-6-PD deficiency); therefore, acetaminophen is generally thought to be safe when given in therapeutic doses to patients with G-6-PD deficiency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some products (eg, chewable tablets) contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause severe hepatotoxicity with excessive intake (in adults &gt;4 g/day) or overdose. Parenteral use is contraindicated in patients with severe hepatic impairment or severe active liver disease. Chronic daily dosing in adults of 5-8 g of acetaminophen over several weeks or 3-4 g/day for 1 year have resulted in liver damage. Do not exceed maximum daily doses (adults &lt;4 g/day); consider all acetaminophen sources  when evaluating the dose of acetaminophen including OTC and prescription combination products. Hypersensitivity and anaphylactic reactions have been reported including life-threatening anaphylaxis; discontinue immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Gelcap and geltab contain benzyl alcohol; some elixir preparations contain benzoic acid; liquid preparations (ie, elixir, liquid, suspension, and drops) may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of acetaminophen products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Elixir, suspension, and some oral drops and liquids contain propylene glycol; in neonates large amounts of propylene glycol (eg, &gt;3000 mg/day I.V.) have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate of absorption may be decreased when given with food high in carbohydrates",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11385104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (intravenous) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with intravenous acetaminophen, therefore, acetaminophen I.V. is classified as pregnancy category C.   Acetaminophen crosses the placenta and can be detected in cord blood, newborn serum, and urine immediately after delivery. An increased risk of teratogenic effects has not been observed following maternal use of acetaminophen during pregnancy. Prenatal constriction of the ductus arteriosus has been noted in case reports following maternal use during the third trimester. The use of acetaminophen in normal doses during pregnancy is not associated with an increased risk of miscarriage or still birth; however, an increase in fetal death or spontaneous abortion may be seen following maternal overdose if treatment is delayed. Frequent maternal use of acetaminophen during pregnancy may be associated with wheezing and asthma in early childhood. The absorption may be delayed and the bioavailability of acetaminophen may be decreased in some women during pregnancy due to delayed gastric emptying.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although not fully elucidated, believed to inhibit the synthesis of prostaglandins in the CNS and peripherally block pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F11402288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Analgesia: 5-10 minutes; Antipyretic: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peak effect: I.V.: Analgesia: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V., Oral: Analgesia: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Antipyretic: &ge;6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     With the exception of half-life (see below), the pharmacokinetic profile in pediatric patients (0-18 years) is similar to adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Primarily absorbed in small intestine (rate of absorption dependent upon gastric emptying); minimal absorption from stomach; varies by dosage form",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~1 L/kg at therapeutic doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 25% at therapeutic concentrations; 8% to 43% at toxic concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: At normal therapeutic dosages, primarily hepatic metabolism to sulfate and glucuronide conjugates, while a small amount is metabolized by CYP2E1 to a highly reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI), which is conjugated rapidly with glutathione and inactivated to nontoxic cysteine and mercapturic acid conjugates. At toxic doses (as little as 4000 mg in a single day), glutathione conjugation becomes insufficient to meet the metabolic demand causing an increase in NAPQI concentrations, which may cause hepatic cell necrosis. Oral administration is subject to first-pass metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: ~2 hours; severe renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): 2-5.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Immediate release: 10-60 minutes (may be delayed in acute overdoses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (&lt;5% unchanged; 60% to 80% as glucuronide metabolites; 20% to 30% as sulfate metabolites; ~8% cysteine and mercapturic acid metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"      see \"Acetaminophen (paracetamol): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; do not take longer than 10 days without physician's advice. Consult your doctor about dosing instructions in children under 2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      2 mg propacetamol (prodrug) = 1 mg paracetamol = 1 mg acetaminophen",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drops may contain saccharin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen (15 mg/kg/dose given orally every 6 hours for 24 hours) did",
"     <b>",
"      not",
"     </b>",
"     relieve the intraoperative or the immediate postoperative pain associated with neonatal circumcision; some benefit was seen 6 hours after circumcision (Howard, 1994).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     There is currently no scientific evidence to support alternating acetaminophen with ibuprofen in the treatment of fever (Mayoral, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on recommendations provided by the Food and Drug Administration (FDA), all over-the-counter (OTC) pediatric single-ingredient acetaminophen liquid products will transition to a single concentration of 160 mg/5 mL; the transition began in 2011 and will continue into 2012. The concentration of acetaminophen infant drops (previously 80 mg/0.8 mL) will now be the same as children&rsquo;s acetaminophen products (160 mg/5 mL) and as a result, new dosing on a volume-per-weight (or volume-per-age) basis will apply. The recommended mg/kg dose is unaffected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In 2011, McNeil Consumer Healthcare announced it had voluntarily reduced the maximum doses and increased the dosing interval on the labeling of some of their acetaminophen OTC products in an attempt to protect consumers from inadvertent overdoses. For example, the maximum dose of Extra Strength Tylenol&reg; OTC was lowered from 4 g/day to 3 g/day and the maximum dose of Regular Strength Tylenol&reg; OTC was lowered from 3900 mg/day to 3250 mg/day. In addition, the dosing interval for Extra Stength Tylenol&reg; OTC was increased from every 4-6 hours to every 6 hours. Healthcare professionals may still prescribe or recommend the 4 g/day maximum to patients (but are advised to use their own discretion and clinical judgment).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allegaert K, Murat I, and Anderson BJ, \"Not All Intravenous Paracetamol Formulations Are Created Equal...\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2007, 17(8):811-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/17596233/pubmed\" id=\"17596233\" target=\"_blank\">",
"        17596233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allegaert K, Palmer GM, and Anderson BJ, \"The Pharmacokinetics of Intravenous Paracetamol in Neonates: Size Matters Most,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2011, 96(6):575-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/21317433/pubmed\" id=\"21317433\" target=\"_blank\">",
"        21317433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics: Committee on Drugs, &ldquo;Acetaminophen Toxicity in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):1020-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/ 11581462 /pubmed\" id=\" 11581462 \" target=\"_blank\">",
"        11581462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anand KJ and International Evidence-Based Group for Neonatal Pain, &ldquo;Consensus Statement for the Prevention and Management of Pain in the Newborn,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2001, 155(2):173-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/11177093/pubmed\" id=\"11177093\" target=\"_blank\">",
"        11177093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anand KJ, Chair, International Evidence-Based Group for Neonatal Pain, personal correspondence, April 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartocci M and Lundeberg S, \"Intravenous Paracetamol: The 'Stockholm Protocol' for Postoperative Analgesia of Term and Preterm Neonates,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2007, 17(11):1120-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/17897288/pubmed\" id=\"17897288\" target=\"_blank\">",
"        17897288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Birmingham PK, Tobin MJ, Fisher DM, et al, \"Initial and Subsequent Dosing of Rectal Acetaminophen in Children: A 24-Hour Pharmacokinetic Study of New Dose Recommendations,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2001, 94(3):385-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/11374595/pubmed\" id=\"11374595\" target=\"_blank\">",
"        11374595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, &ldquo;Perioperative Use of High-Dose Rectal Acetaminophen,&rdquo;",
"      <i>",
"       Pediatr Pharm",
"      </i>",
"      , 2001, 7(9), file://www.medscape.com/viewarticle/415082.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahn TW, Henneberg SW, Holm-Knudsen RJ, et al, \"Pharmacokinetics of Rectal Paracetamol After Repeated Dosing in Children,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2000, 85(4):512-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/11064607/pubmed\" id=\"11064607\" target=\"_blank\">",
"        11064607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howard CR, Howard FM, and Weitzman ML, &ldquo;Acetaminophen Analgesia in Neonatal Circumcision: The Effect on Pain,&rdquo;",
"      <i>",
"       Pediatrics,",
"      </i>",
"      1994, 93(4):641-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/8134222 /pubmed\" id=\"8134222 \" target=\"_blank\">",
"        8134222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayoral CE, Marino RV, Rosenfeld W, et al, &ldquo;Alternating Antipyretics: Is This An Alternative?&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5):1009-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/10790455 /pubmed\" id=\"10790455 \" target=\"_blank\">",
"        10790455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Anker JN and Tibboel D, \"Pain Relief in Neonates: When to Use Intravenous Paracetamol,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2011, 96(6):573-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/21441241/pubmed\" id=\"21441241\" target=\"_blank\">",
"        21441241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Lingen RA, Deinum HT, Quak CM, et al, \"Multiple-Dose Pharmacokinetics of Rectally Administered Acetaminophen in Term Infants,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1999, 66(5):509-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/10579478/pubmed\" id=\"10579478\" target=\"_blank\">",
"        10579478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson-Smith EM and Morton NS, \"Survey of I.V. Paracetamol (Acetaminophen) Use in Neonates and Infants Under 1 Year of Age by UK Anesthetists,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2009, 19(4):329-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/15/19705/abstract-text/19335345/pubmed\" id=\"19335345\" target=\"_blank\">",
"        19335345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13028 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19705=[""].join("\n");
var outline_f19_15_19705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391964\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129318\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129319\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050747\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426603\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050742\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129293\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050752\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11385126\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11402271\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050751\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129376\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129374\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050755\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050741\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050740\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129365\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050758\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11385104\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630924\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050739\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11402288\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050754\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050746\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050756\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13028\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13028|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=related_link\">",
"      Acetaminophen (paracetamol): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=related_link\">",
"      Acetaminophen (paracetamol): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_15_19706="Cystic fibrosis: Overview of gastrointestinal disease";
var content_f19_15_19706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Overview of gastrointestinal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/15/19706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19706/contributors\">",
"     Julie P Katkin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19706/contributors\">",
"     Karen Schultz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/15/19706/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19706/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19706/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/15/19706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/15/19706/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/15/19706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) generally is thought of as a lung disease since much of the associated morbidity and mortality is related to pulmonary complications. A discussion of the pulmonary manifestations of CF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrointestinal complications have become an increasingly important cause of morbidity in patients with CF, in part because of improved life expectancy. This topic review provides an overview of the gastrointestinal manifestations of CF. Pancreatic insufficiency, which is one of the most clinically important gastrointestinal issues, and other nutritional issues are addressed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29095?source=see_link\">",
"     \"Cystic fibrosis: Assessment and management of pancreatic insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link\">",
"     \"Cystic fibrosis: Nutritional issues\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The underlying pathophysiology of cystic fibrosis is related to abnormal chloride transport caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) located on chromosome 7. The mutations cause the production of abnormally tenacious mucus and secretions in the lungs, gut, pancreas, and hepatobiliary system. As a result, the lumens of these organs become obstructed leading to the clinical findings associated with this disease process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CATEGORIES OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal manifestations of CF can be broken down into three categories: intestinal, pancreatic, and hepatobiliary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal abnormalities include gastroesophageal reflux disease (GERD), meconium ileus (MI), distal intestinal obstruction syndrome (DIOS), intussusception, small intestine bacterial overgrowth, constipation, and rectal prolapse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GERD is estimated to be six to eight times more common in patients with CF than in otherwise healthy children. Multiple mechanisms may contribute to the increased prevalence.",
"     </li>",
"     <li>",
"      MI is a disorder of the neonate characterized by the obstruction of the small intestines by meconium. It is the presentation of CF in approximately 10 percent of patients and is virtually pathognomonic of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/1\">",
"       1",
"      </a>",
"      ]. Its counterpart in the older child is DIOS, which is the complete or partial obstruction of the bowel lumen by inspissated intestinal contents. Both MI and DIOS are associated with pancreatic insufficiency. &nbsp;",
"     </li>",
"     <li>",
"      Other intestinal complications include constipation and intussusception. The latter should be considered in children with CF who presents with signs of obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pancreatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic insufficiency is present from birth in most patients with CF. Insufficient secretion of enzymes leads to malabsorption of fat (with steatorrhea) and protein. Failure to thrive is a common presenting sign. In severe cases, the fat malabsorption can lead to deficiencies of the fat soluble vitamins A, D, E, and K; however, routine vitamin supplementation has made clinical evidence of vitamin deficiency uncommon. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Pancreatic insufficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most patients with cystic fibrosis develop progressive pancreatic damage as a result of defective ductular and acinar pancreatic secretion. This can ultimately lead to chronic pancreatitis, and also to dysfunction of the endocrine pancreas, leading to glucose intolerance and CF-related diabetes. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Pancreatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hepatobiliary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic liver disease is a common finding at autopsy; antemortem elevations of serum alkaline phosphatase occur in at least 10 percent of patients and lobular hepatomegaly may be found incidentally [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal biliary cirrhosis caused by inspissated bile is present in many patients. In 10 to 20 percent of patients this leads to progressive liver disease, with progressive periportal fibrosis, multilobular cirrhosis, and symptomatic portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Several observational studies have suggested that administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    may slow the progression of liver disease related to CF, but an unequivocal effect of this therapy has not been confirmed in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholelithiasis has been reported in up to 12 percent of patients, and may result from excessive loss of bile acids in the stool with consequent production of lithogenic bile [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Asymptomatic cholelithiasis generally does not require treatment, although prophylactic cholecystectomy may be performed in such patients prior to lung transplantation in some centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GASTROESOPHAGEAL REFLUX DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have suggested an association between gastroesophageal reflux disease (GERD) and CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. However, the magnitude of the association has not been well-defined, since GERD is common in otherwise healthy children and other disorders can cause features that may be confused with GERD (",
"    <a class=\"graphic graphic_table graphicRef80386 \" href=\"UTD.htm?14/15/14589\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the only studies that included a control group focused on 68 children older than five years who were assessed for symptoms and also underwent 24-hour esophageal pH recording [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/11\">",
"     11",
"    </a>",
"    ]. Symptoms were compared to 23 asymptomatic siblings. Children with CF were more likely to experience regurgitation (21 versus 0 percent) and heartburn (27 versus 6 percent). In addition, reflux episodes and esophageal acid exposure on pH recording were significantly higher than published control data.",
"   </p>",
"   <p>",
"    Another study found that GERD was present in 21 of 26 children (81 percent) younger than 60 months as assessed by esophageal pH recording or history [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/8\">",
"     8",
"    </a>",
"    ]. Other reports have suggested that affected children may develop complications from GERD such as esophagitis and esophageal strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. A predisposition to GERD appears to persist into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal mechanism causing GERD in children with CF appears to be related to transient relaxation of the lower esophageal sphincter (LES), which is also the most common mechanism leading to GERD in patients without CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other mechanisms may also contribute to GERD in children with CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/7-10,12,14\">",
"     7-10,12,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased intra-abdominal pressure due to chronic coughing and wheezing",
"     </li>",
"     <li>",
"      Absence of the normal basal tone of the LES",
"     </li>",
"     <li>",
"      The mechanical effect of a depressed diaphragm caused by lung hyperinflation",
"     </li>",
"     <li>",
"      Supine positioning during chest physiotherapy",
"     </li>",
"     <li>",
"      Medications that reduce LES pressure, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and alpha-adrenergic agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and methods to diagnose GERD in children with CF are the same as those seen in children without CF. The most common symptoms vary according to age, although overlap may exist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A particularly important consideration in children with CF is whether GERD is contributing to respiratory symptoms, an association that is difficult to predict accurately based upon diagnostic testing. The best evidence supporting such an association is improvement in pulmonary status after aggressive medical management of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of management of GERD in children with CF are similar to those in otherwise healthy children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are a few management issues that are specific to individuals with CF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest physiotherapy should be performed prior to meals, since physiotherapy on a full stomach promotes the development of reflux.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       Sucralfate",
"      </a>",
"      (and antacids) should be given at least two hours before or one hour after other oral medications since they may block the absorption of other medications used to treat CF.",
"     </li>",
"     <li>",
"      Inhibition of gastric acid secretion using proton pump inhibitors (PPIs) is an appropriate treatment strategy for patients with CF and GERD. Several clinical considerations are relevant to this decision:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A few studies have suggested that PPIs are associated with a slightly increased risk for pulmonary infections in patients without CF [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. However, a retrospective study in patients with CF did not reveal such an association [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are theoretical concerns that chronic use of PPIs may have adverse effects on bone health. These concerns are based on a possible association between PPI use and risk of fractures in older adults without CF, but the evidence is conflicting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59976497#H59976497\">",
"       \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Hip fracture and calcium malabsorption'",
"      </a>",
"      .) Important measures to prevent and monitor for bone disease in patients with CF are discussed in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H8#H8\">",
"       \"Cystic fibrosis: Nutritional issues\", section on 'Bone disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acid suppression can improve fat absorption in some patients with pancreatic insufficiency who have fat malabsorption despite adequate doses of pancreatic enzyme replacement therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29095?source=see_link&amp;anchor=H10#H10\">",
"       \"Cystic fibrosis: Assessment and management of pancreatic insufficiency\", section on 'Dosing considerations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical management of GERD can be considered in patients with complications of GERD including erosive esophagitis, esophageal strictures, failure to thrive, or uncontrolled respiratory disease that is refractory to medical management. However, causes of these symptoms other than GERD should be carefully excluded, and continued symptoms despite adequate acid suppression should serve as a warning that the symptoms may not be due to esophageal acid exposure and therefore may not be relieved after antireflux surgery. In a report of children with cystic fibrosis and GERD, nearly half of the children had ongoing symptoms of GERD after fundoplication, and there was little improvement in pulmonary function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/18\">",
"       18",
"      </a>",
"      ]. In addition, 12 percent had complications that required a subsequent surgical procedure.",
"      <br/>",
"      <br/>",
"      If fundoplication is undertaken after full consideration of this suboptimal prognosis, the presence of CF should not be a deterrent, but optimal pulmonary status should be achieved prior to surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11986089\">",
"    <span class=\"h1\">",
"     MECONIUM ILEUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients with CF present with meconium ileus (MI). Conversely, most series suggest that 80 to 90 percent of infants with meconium ileus have CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/20\">",
"     20",
"    </a>",
"    ], although a few series report higher proportions of non-CF MI, particularly in low birthweight infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/21\">",
"     21",
"    </a>",
"    ]. MI is characterized by intestinal obstruction at the level of the terminal ileum with inspissated meconium. Infants generally present during the first three days of life with abdominal distension with or without vomiting and failure to pass meconium.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MI is &ldquo;complex&rdquo; if it is complicated by gastrointestinal pathology, including intestinal perforation, meconium peritonitis, atresia, or volvulus. Prenatal perforation may cause meconium peritonitis, which can cause calcifications visible on abdominal radiography. Approximately 40 percent of MI in newborns with CF is complex. &nbsp;",
"     </li>",
"     <li>",
"      MI is &ldquo;simple&rdquo; if there is no associated gastrointestinal pathology. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with MI are initially stabilized with nasogastric decompression and correction of fluid and electrolyte abnormalities. The diagnosis is confirmed by radiography with a water-soluble contrast enema, which typically reveals a small-caliber colon (microcolon) and meconium pellets in the terminal ileum. The ileum proximal to the obstruction is dilated. Contrast radiography is avoided if there is prior evidence of perforation. &nbsp;",
"   </p>",
"   <p>",
"    If simple MI is confirmed by the diagnostic enema, it is usually managed by administration of hyperosmolar enema (typically diluted sodium meglumine diatrizoate, Gastrografin), closely monitored by fluoroscopy. The hyperosmolar contrast breaks up the meconium plug. Early series reported 60 to 80 percent success in relieving the obstruction using this method [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], but more current series suggest success rates of 30 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Complications occur in 2 to 20 percent of these procedures and include intestinal perforation and fluid shifts with hypotension and shock. Higher rates of success and complications may both depend on use of higher instillation pressures and multiple attempts.",
"   </p>",
"   <p>",
"    Surgical approaches are used for complicated MI and for some cases of simple MI that do not clear with nonoperative intervention. Operative procedures include simple enterotomy with lavage, double enterostomy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resection of dilated, perforated, or atretic bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISTAL INTESTINAL OBSTRUCTION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal intestinal obstruction syndrome (DIOS), formerly known as \"meconium ileus equivalent,\" is characterized by an acute complete or partial obstruction of the ileocecum by intestinal contents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. By contrast, constipation in patients with CF is characterized by gradual onset of fecal impaction of the total colon. DIOS can occur at any age, but it is more common in older patients and those with pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIOS occurs in 10 to 47 percent of CF patients, depending upon the criteria used to make the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/19,32,33\">",
"     19,32,33",
"    </a>",
"    ]. The youngest reported patient was five months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ] although it is uncommon below the age of five years; it is most common in patients older than 20 years of age. DIOS tends to be recurrent and is more common in patients with a history of meconium ileus, suggesting that there is an underlying predisposition in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, the development of DIOS appears to be caused by non-genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/3\">",
"     3",
"    </a>",
"    ]. There is no relationship between the development of DIOS and pulmonary exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for developing DIOS include severe genotype (eg, delta F508), pancreatic insufficiency, poorly controlled fat malabsorption, dehydration, and history of meconium ileus or prior episodes of DIOS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/34\">",
"     34",
"    </a>",
"    ]. DIOS also is more common in patients who have undergone organ transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIOS is caused by inspissated intestinal contents that completely or partially block the small intestinal lumen, most commonly at the ileocecal junction.",
"   </p>",
"   <p>",
"    The pathogenesis of DIOS is not fully understood, but several mechanisms have been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of patients with DIOS have pancreatic insufficiency. There have been only a few case reports of DIOS in patients with adequate pancreatic function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/30\">",
"       30",
"      </a>",
"      ]. This association is supported by the observation that inadequate doses of pancreatic enzymes have been implicated as a factor in the etiology of DIOS [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intestinal dysmotility, either intrinsic or iatrogenic, has also been suggested as a factor in the development of this disorder. Intrinsic dysmotility has been implicated to explain the high rate of recurrence in some patients. The presence of constipation in 42 percent of individuals with DIOS also supports this reasoning [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other factors that may have a role in the development of DIOS are abnormal mucins and water and electrolyte composition of the intestinal contents [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. While acute episodes of dehydration and changes in diet have been associated with the development of DIOS, a common set of precipitating factors has not been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common manifestation of DIOS is crampy abdominal pain, which generally is located in the right lower quadrant. The onset of symptoms usually is acute, and the symptoms tend to become progressively severe over time. Other features include abdominal distension, weight loss, and poor appetite. Patients usually are constipated but also may have diarrhea or even a normal stool pattern. Vomiting may ensue when complete obstruction develops. On examination, a mass may be palpated in the right lower quadrant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIOS can be diagnosed in patients with CF who present with the classical triad of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      A right lower quadrant mass",
"     </li>",
"     <li>",
"      Stool in the distal small intestine and right colon on plain radiographs. The stool is usually described as \"bubbly\" or granular in appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/30\">",
"       30",
"      </a>",
"      ]. Other characteristic findings on plain film include air-fluid levels and small bowel dilatation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DIOS must be distinguished from chronic constipation, in which the onset of symptoms is more gradual and the stool is distributed more evenly throughout the colon. The differential diagnosis of DIOS also includes appendicitis, volvulus, intussusception, and ovarian problems [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14,30\">",
"     14,30",
"    </a>",
"    ]. Other diagnostic studies should be performed based upon the patient's clinical findings if the diagnosis is unclear. Basic blood work can be performed including a complete blood count, liver enzymes, urinalysis and culture, and serum amylase and lipase to evaluate for other possible causes of abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional radiologic imaging also can aid in the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ]. An abdominal ultrasound can identify an obstructing mass but cannot always rule out appendicitis or intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/19\">",
"     19",
"    </a>",
"    ]. On CT scan, findings characteristic of DIOS include proximal small-bowel dilation and inspissated fecal material in the distal ileum; the scan also helps to exclude other causes of the symptoms.",
"   </p>",
"   <p>",
"    Alternatively, a water-soluble contrast enema can be useful; the absence of contrast material in the terminal ileum is suggestive of DIOS. Tween-80 (polysorbate 80, a soap- or solvent-like compound) may be added to the Gastrografin, which may be therapeutic as well as diagnostic. The amount of",
"    <span class=\"nowrap\">",
"     Tween-80/Gastrografin",
"    </span>",
"    varies from patient to patient and is best left up to the radiologist. Risks associated with Gastrografin enemas include perforation, hypovolemia, and bowel ischemia, and should therefore only be performed by an experienced radiologist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with incomplete (impending) DIOS usually respond to oral rehydration and osmotic laxatives. Those with complete DIOS or signs of peritonitis may require surgery and should be urgently evaluated by a surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In surgical and non-surgical cases, initial management should be aimed at correcting fluid and electrolyte abnormalities. A nasogastric tube should be considered for decompression, especially in patients who are vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once electrolyte abnormalities have been corrected, treatment should be aimed at removal of the inspissated plug. This can be accomplished using a combination of enemas and laxatives. Treatment is generally tailored to the severity of the episode.",
"   </p>",
"   <p>",
"    For patients who are not vomiting, each of the following approaches has been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral polyethylene glycol (PEG, eg, Miralax&reg;), given at a dose of 2",
"      <span class=\"nowrap\">",
"       grams/kg/day",
"      </span>",
"      (maximum 80 to 100",
"      <span class=\"nowrap\">",
"       grams/day).",
"      </span>",
"      This has been used successfully and is generally well tolerated, especially if given before complete obstruction has occurred.",
"     </li>",
"     <li>",
"      A balanced electrolyte intestinal lavage solution (such as GoLYTELY&reg;), is administered either orally or nasogastrically (particularly in children) at a rate of 20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour (maximum 1",
"      <span class=\"nowrap\">",
"       L/hour)",
"      </span>",
"      over eight hours. Children generally require a total of 2 to 3 liters and adults 5 to 6 liters [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sodium meglumine diatrizoate (Gastrografin) can be administered orally or by nasogastric tube [",
"      <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/39\">",
"       39",
"      </a>",
"      ]. For children younger than six years, an appropriate dose is 50 mL of Gastrografin in 200 mL of water or juice. For older patients, 100 mL of Gastrografin is diluted in 400 mL of water or juice. In each age group, half of this dose is given on subsequent days if needed to complete the clean-out. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients presenting with bilious vomiting or other evidence of complete intestinal obstruction, or for those who do not respond to the above measures, a hyperosmolar enema (sodium meglumine diatrizoate, Gastrografin) can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. The enema consists of 100 mL of Gastrografin, diluted in 400 mL water; it is administered under fluoroscopic guidance to visually confirm clearance of the obstruction as the enema refluxes retrograde through the ileocecal junction. Potential complications of hyperosmolar enemas include depletion of intravascular fluid with hypotension and shock, or bowel perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/34\">",
"     34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     Mineral oil",
"    </a>",
"    and fleet enemas are usually not effective for the distal ileal obstruction found in DIOS.",
"   </p>",
"   <p>",
"    A few patients do not respond to the medical management described above, or develop evidence of intestinal ischemia. In this case, surgical laparotomy and decompression is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the inspissated plug has been eliminated, it is important to initiate appropriate pancreatic enzyme replacement. Furthermore treatment aimed at preventing further episodes should be instituted, since DIOS recurs frequently. This may consist of routine treatment with laxatives, stool softeners, or prokinetic agents. One approach that is usually well tolerated is chronic administration of oral PEG at a dose of 0.5 to 1",
"    <span class=\"nowrap\">",
"     gram/kg/day",
"    </span>",
"    (maximum 40",
"    <span class=\"nowrap\">",
"     grams/day)",
"    </span>",
"    for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/34\">",
"     34",
"    </a>",
"    ]. The clinician should also optimize pancreatic enzyme treatment and address potential adherence issues, and encourage adequate hydration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14,30\">",
"     14,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Pancreatic insufficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTUSSUSCEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intussusception occurs in approximately 1 percent of patients with CF. Similar to DIOS, intussusception is related to inadequate pancreatic enzyme supplementation with inspissated bowel contents serving as the lead point. Clinically, it is characterized by colicky abdominal pain, vomiting, a palpable mass, and rectal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Diagnosis can be made with ultrasound, or with a contrast enema, which may also be therapeutic. Surgery is required if less invasive management is unsuccessful or the patient develops signs of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7111548\">",
"    <span class=\"h1\">",
"     APPENDICEAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendicitis in patients with CF often has an atypical presentation which can mimic symptoms of DIOS or other CF-related intestinal diseases. In a series of 33 CF patients with appendiceal disease, only 15 (45 percent) presented with classic symptoms of abdominal pain shifting to the right lower quadrant, focal RLQ abdominal pain and elevated white blood cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/43\">",
"     43",
"    </a>",
"    ]. An additional four patients (12 percent) had acute appendicitis presenting with mild or atypical symptoms. The remaining 14 patients had tense mucoid distension of the appendix, which presented with chronic intermittent focal RLQ pain without fever, or with intussusception. In these cases the tense mucoid distension was responsible for the symptoms, which resolved after resection. In other patients with CF, mucoid distension of the appendix is asymptomatic and is found incidentally at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SMALL INTESTINE BACTERIAL OVERGROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small intestine bacterial overgrowth (SIBO) is a condition in which the normally low bacterial content in the upper GI tract significantly increases. Bacteria can transform normal nutrients into nonabsorbable and toxic substances leading to enterocyte damage, malabsorption, and eventually malnutrition. This condition was first recognized in patients following gastrointestinal surgery but now is described in other clinical settings, including in patients with malnutrition or disorders affecting gastrointestinal motility. Some studies using breath hydrogen testing report that individuals with CF are susceptible to SIBO, perhaps because they often have one or more of these risk factors, particularly decreased intestinal motility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. SIBO has also been described in a mouse model of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/47\">",
"     47",
"    </a>",
"    ]. Other studies suggest that patients with CF have false positive breath hydrogen tests, perhaps because of underlying malnutrition or dysmotility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SIBO can contribute to fat malabsorption and malnutrition by deconjugating bile salts and interfering with their ability to emulsify fats in the intestinal lumen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H11#H11\">",
"     \"Cystic fibrosis: Nutritional issues\", section on 'Small intestine bacterial overgrowth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical symptoms of SIBO may be nonspecific and include bloating, flatulence, abdominal pain, watery diarrhea, dyspepsia, and weight loss or failure to gain weight. The disorder may be diagnosed by hydrogen breath testing, but this technique is only moderately accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because accurate, definitive tests to establish the presence of SIBO are lacking, empiric trials of treatment may be given to patients who are suspected of having SIBO. Oral antibiotics, that are either absorbable or nonabsorbable, can be used. Sometimes this treatment trial results in dramatic improvement in gastrointestinal symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in nutritional status. Other treatment considerations for SIBO are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECTAL PROLAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal prolapse occurs in approximately 20 percent of patients with CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/50\">",
"     50",
"    </a>",
"    ]. It has been associated with constipation, diarrhea, and malnutrition. It occurs most frequently in toddler-aged children who are toilet training but can occur at any age. It often is associated with cough in older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/48/32519?source=see_link\">",
"     \"Overview of rectal prolapse in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prolapse may involve only the mucosa or may involve all layers of the ano-rectum. Families should be taught how to manually reduce the intussusception to prevent bowel edema. Surgical intervention rarely is indicated. If recurrent, rectal prolapse may indicate the need to increase pancreatic enzyme replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/14,51\">",
"     14,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PANCREATIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pancreatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic insufficiency is the most common gastrointestinal complication of CF, affecting approximately 85 percent of patients at some time in their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/52\">",
"     52",
"    </a>",
"    ]. The major consequences of pancreatic insufficiency are due to fat malabsorption secondary to decreased production of pancreatic enzymes. As a result, patients with undiagnosed or under-treated pancreatic disease are at risk for steatorrhea, malnutrition and fat-soluble vitamin deficiencies.",
"   </p>",
"   <p>",
"    The diagnosis and management of pancreatic insufficiency in this population, including strategies for pancreatic enzyme replacement and fibrosing colonopathy, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29095?source=see_link\">",
"     \"Cystic fibrosis: Assessment and management of pancreatic insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreatic insufficiency is an important contributor to the nutritional problems in patients with CF, which include growth failure, fat-soluble vitamin deficiencies, and bone disease. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link\">",
"     \"Cystic fibrosis: Nutritional issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis develops in about 10 percent of CF patients with pancreatic sufficiency, and is rare among those with pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/53\">",
"     53",
"    </a>",
"    ]. Accordingly, most patients who develop pancreatitis have at least one \"mild\" CFTR mutation (Class IV or V). In such patients, defective ductular and acinar pancreatic secretion leads to recurrent or chronic pancreatitis, which in turn causes a decline of pancreatic exocrine function. Among patients with pancreatic sufficiency at the time of the first episode of pancreatitis, about 20 percent subsequently experience a decline of pancreatic function and become pancreatic insufficient.",
"   </p>",
"   <p>",
"    Pancreatitis in CF patients typically presents during late adolescence or early adulthood. On rare occasions pancreatitis may be the initial presenting symptom of CF.",
"   </p>",
"   <p>",
"    An increased prevalence of CFTR mutations has been observed in patients with idiopathic chronic and acute pancreatitis, suggesting that certain CF genotypes (perhaps in combination with environmental or genetic cofactors) predispose to this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42727?source=see_link\">",
"     \"Causes of chronic pancreatitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CF-related diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with exocrine pancreatic insufficiency also develop endocrine pancreatic dysfunction, which ultimately progresses to cystic fibrosis related diabetes (CFRD). The risk of developing CFRD increases with advancing age, the presence of pancreatic insufficiency, the delta F508 homozygous genotype, and female gender [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In studies in which diabetes mellitus was detected through routine screening with an oral glucose tolerance tests, approximately 25 percent of patients had developed CFRD by 20 years of age, and the prevalence increased markedly with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. The onset of CFRD is insidious; clinical symptoms include failure to gain weight, poor growth velocity, delayed progression of puberty, or an unexplained chronic decline in pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of CFRD are unique and share features with both type I and type II diabetes, with both decreased insulin production and insulin resistance. Patients with CF-related pancreatic disease usually have decreased insulin secretion, but in its early stages, glucose tolerance may be either normal or decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Some have normal glucose tolerance because of the unusual combination of increased hepatic glucose production and increased peripheral glucose utilization; the latter adaptation is initially able to counteract the effects of insulin deficiency. When impaired glucose tolerance or overt diabetes develops, it is characterized by reductions in both peripheral glucose utilization and hepatic insulin sensitivity.",
"   </p>",
"   <p>",
"    The standard medical therapy for CFRD is subcutaneous insulin, whether or not fasting hyperglycemia is present [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. By contrast, patients with impaired glucose tolerance (ie, 2h plasma glucose on an oral glucose tolerance test between 140 and 199",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    are not routinely treated with insulin but should be followed closely for signs of deterioration. Screening recommendations for CFRD are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystic fibrosis: Nutritional issues\", section on 'CF-related diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HEPATOBILIARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other gastrointestinal complications of CF, hepatobiliary disease is becoming increasingly common, most likely due to the improved life expectancy. Liver disease in CF can often be difficult to diagnose because patients may remain asymptomatic until late in the disease process, and screening tests correlate poorly with disease severity. Management goals are to identify disease early; to prevent and treat complications; and to educate the families regarding symptoms and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of liver disease in CF is not well-established. Post-mortem examinations have demonstrated pathologic changes in the liver in up to 72 percent of patients over the age of 24 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/66\">",
"     66",
"    </a>",
"    ]. Approximately 30 percent of patients have elevated levels of AST",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alkaline phosphatase, the clinical significance of which is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Clinically significant cirrhosis occurs in 1 to 2 percent of patients with CF with the highest prevalence in patients aged 18 to 24 years. In 1996 liver disease was the primary cause of death in 1.6 percent of CF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Almost all patients with severe CF-related liver disease are diagnosed before age 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/67\">",
"     67",
"    </a>",
"    ]. Consequently, among patients with CF most liver transplants are performed in the pediatric age group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the liver, CFTR is located in the biliary epithelium. Bile produced in patients with CF is thick and tenacious, causing blockage of the intrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2\">",
"     2",
"    </a>",
"    ]. Other factors that may contribute to the development of liver disease in CF include impaired secretion of mucins from the submucosal glands and increased glycine-conjugated bile acids. Both of these are thought to contribute to the decreased flow and increased concentration of the bile [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Obstruction of the biliary ductules causes the release of pro-inflammatory agents and growth factors that induce the synthesis of collagen in the portal tracts, leading to progressive fibrosis and eventually cirrhosis. The progression from cholestasis to cirrhosis may take years to decades [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Only a minority of CF patients develops severe CF-related liver disease; genetic variation in genes other than CFTR may be an important determinant of susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may also develop steatosis (the accumulation of fat in the liver), which may be related to multiple factors, including malnutrition, essential fatty acid deficiency, ethanol ingestion in older patients, or the genetic defect itself. The relationship between hepatic steatosis and the development of cirrhosis in CF is unclear.",
"   </p>",
"   <p>",
"    The production of abnormal mucins may also contribute to the formation of gallstones. Patients with CF have a higher prevalence of gallstones than age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/69\">",
"     69",
"    </a>",
"    ]. Other hepatobiliary abnormalities in CF include neonatal cholestasis, hepatic steatosis, and micro-gallbladder. The pathogenesis of micro-gallbladder in CF is unclear. One theory is that it is caused by a developmental abnormality of the fetal gallbladder, which has high expression of CFTR [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Neonatal cholestasis often is associated with a history of meconium ileus and prolonged parenteral nutrition. There may be an increased risk for the subsequent development of cirrhosis in this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple presentations of liver disease in CF (",
"    <a class=\"graphic graphic_table graphicRef81636 \" href=\"UTD.htm?1/9/1179\">",
"     table 2",
"    </a>",
"    ), the most common of which are asymptomatic elevation in liver enzyme tests and hepatosplenomegaly. A subset of patients develops cirrhosis, which may progress to end-stage liver disease. Other presentations include cholecystitis and choledocholithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Cholelithiasis has been reported in up to 12 percent of patients and may result from excessive loss of bile acids in the stool with consequent production of lithogenic bile [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant liver disease is rare during infancy, but may be the initial symptom of CF. Most infants present with prolonged conjugated hyperbilirubinemia; a few display massive hepatomegaly caused by fatty infiltration of the liver from malnutrition. The hepatomegaly tends to regress with improved nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/66\">",
"     66",
"    </a>",
"    ]. Rarely, biliary obstruction can be very severe during infancy, mimicking biliary atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older infants and children hepatobiliary disease is usually detected when routine screening reveals abnormal liver enzymes. The Cystic Fibrosis Foundation recommends that liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and alkaline phosphatase) be checked yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Gamma glutamyl transpeptidase (GGT) or 5' nucleotidase are typically elevated out of proportion to AST and ALT. Serum bilirubin levels are generally not elevated until late in the disease course. These children may also present with hepatomegaly or splenomegaly. It is important to palpate both lobes of the liver since only one may be enlarged. With increasing splenomegaly, patients may develop left upper quadrant pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with advanced liver disease may develop portal hypertension, nutritional deficiencies, and hepatic synthetic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Portal hypertension occurs in 2 to 5 percent of patients with CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. In contrast to other forms of chronic liver disease, cutaneous manifestations such as jaundice, palmar erythema, and spider hemangiomata are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Gastrointestinal variceal hemorrhage and encephalopathy also are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having liver involvement based upon the clinical features described above should undergo further evaluation. The intensity of the evaluation should be guided by the clinical setting. Asymptomatic patients identified because of abnormal liver enzymes can generally be observed for six months prior to further evaluation. In patients with persistent elevations, the evaluation should include a careful history asking specifically about the neonatal course, history of jaundice, change in activity level, change in stool pattern, abdominal pain or nausea, weight loss, medication intake including over-the-counter medications and supplements, history of blood transfusion, and family history.",
"   </p>",
"   <p>",
"    Physical examination should include careful palpation and percussion of the entire liver noting contour and texture. As mentioned above, hepatosplenomegaly is common when liver disease is present. Other manifestations of chronic liver disease (such as jaundice, spider angiomata, palmar erythema, and ascites) are uncommon, but nevertheless should be sought. Signs or symptoms of nutritional deficiencies should also be noted.",
"   </p>",
"   <p>",
"    Additional laboratory evaluation should include measurement of total protein, albumin, cholesterol, and prothrombin time; blood ammonia; glucose; and a complete blood count. Other causes of liver disease need to be considered, including infectious hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency, hemochromatosis, and autoimmune disease. Appropriate laboratory tests should be sent when indicated. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Radiologic evaluation should begin with an abdominal ultrasound, which is most helpful for detecting abnormalities in the biliary tree. The ultrasound also can give an impression of the liver's contour and texture and identify ascites. Doppler analysis can detect abnormalities suggestive of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Pulmonary disease and right heart failure (cor pulmonale) may also lead to hepatic congestion, modest alterations in transaminases, and dilated hepatic veins.",
"   </p>",
"   <p>",
"    An upper gastrointestinal endoscopy to evaluate for esophageal varices can be considered in patients with clinical or radiographic signs of portal hypertension. However, it is not recommended for all patients with suspected liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. Nonselective beta-blockers reduce the risk of bleeding in adults with varices; however, caution should be used in patients with cystic fibrosis since there may be adverse consequences in patients with airway reactivity. There are no studies addressing the use of beta blockers in adolescents; therefore, each case should be evaluated in conjunction with a gastrointestinal specialist prior to initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies that may be considered based upon the clinical setting include hepatobiliary scintigraphy (in patients suspected of having cholecystitis) and endoscopic retrograde cholangiopancreatography (ERCP), which is used only rarely in children. ERCP can define the biliary anatomy and may be required in patients with choledocholithiasis. Visualization of the biliary tree also can be accomplished with magnetic resonance cholangiopancreatography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20536?source=see_link\">",
"     \"ERCP for biliary disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A liver biopsy can be considered in patients in whom the diagnosis is unclear (such as those suspected of having a concomitant liver disease) and in whom histologic confirmation of the severity of liver disease is desired. However, the limited treatment options and influence that the biopsy results would have on management should be weighed when making a decision regarding a liver biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important parts of management of liver disease in CF is optimization of nutrition including the correction of abnormalities of fat-soluble vitamins, essential fatty acids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , and choline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies and one randomized trial have suggested that administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) may delay the progression of liver disease related to CF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/5,72,73\">",
"     5,72,73",
"    </a>",
"    ], but an unequivocal effect of this therapy has not been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/74\">",
"     74",
"    </a>",
"    ]. Nevertheless, it is commonly used for CF patients with clinically significant cholestasis, fibrosis or cirrhosis, as suggested by an expert panel [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. UDCA is typically initiated if ALT, AST exceed three times the upper limit of normal for at least three months",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if GGT is significantly elevated, and given at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day in two divided doses, which is somewhat higher than doses used for other cholestatic liver diseases. A small randomized trial suggests that administration of UDCA at this dose improves some biochemical and clinical parameters in patients with CF-related liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/4,72\">",
"     4,72",
"    </a>",
"    ]. Expert opinion differs as to whether it should be used for all patients with CF-related liver disease, or only those with significant cholestasis and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/4,65\">",
"     4,65",
"    </a>",
"    ]; one small study in children who presented with meconium ileus at birth suggested that treatment with UCDA reduced the likelihood of developing chronic liver disease by nine years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/75\">",
"     75",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The proposed benefit from UDCA is related to displacement of cytotoxic bile acids that may initiate and perpetuate hepatic injury by a non-toxic bile acid. It also may have a cytoprotective effect and increase bicarbonate secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2\">",
"     2",
"    </a>",
"    ]. Gallstones in CF are not responsive to therapy with UDCA, most likely because their main component is not cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65,76\">",
"     65,76",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Cholelithiasis and upper gastrointestinal bleeding should be treated as in other patients with these conditions. Asymptomatic cholelithiasis generally does not require treatment, although prophylactic cholecystectomy is performed in such patients prior to lung transplantation in some centers.",
"   </p>",
"   <p>",
"    Patients with liver failure or end-stage liver disease should be considered for liver transplantation. Overall outcome of patients with CF after transplant appears similar to those with other forms of liver disease with a one-year survival of approximately 85 percent and a five-year survival of 64 to 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/2,65,66,77\">",
"     2,65,66,77",
"    </a>",
"    ]. Patients should be referred early since waiting time for a liver may exceed one year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"     65",
"    </a>",
"    ]. CF patients in whom both lung and liver disease are advanced are candidates for liver-lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/15/19706/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H26#H26\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Lung transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=see_link\">",
"       \"Patient information: Cystic fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5203077\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5203223\">",
"    <span class=\"h2\">",
"     Intestine",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroesophageal reflux disease (GERD) is estimated to be six to eight times more common in patients with CF than in otherwise healthy children. A number of other disorders can cause features that may be confused with GERD (",
"      <a class=\"graphic graphic_table graphicRef80386 \" href=\"UTD.htm?14/15/14589\">",
"       table 1",
"      </a>",
"      ). The principles of management of GERD in children with CF are similar to those in otherwise healthy children. The decision of whether to use proton pump inhibitors (PPIs) depends on several considerations, including whether the GERD is exacerbating lung disease and whether acid suppression may improve the efficacy of pancreatic enzyme replacement therapy (PERT), as well as theoretical concerns about PPI effects on bone density. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastroesophageal reflux disease'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Distal ileal obstruction syndrome (DIOS) is caused by inspissated intestinal contents that completely or partially block the small intestinal lumen, most commonly at the ileocecal junction. It tends to occur in patients with pancreatic insufficiency and may be triggered by inadequate PERT dosing. DIOS is characterized by progressive crampy abdominal pain in the right lower quadrant, often with a right lower quadrant mass, and sometimes progressing to vomiting. Management focuses on correcting fluid and electrolyte abnormalities and removing the inspissated plug using osmotic agents. Surgery rarely is needed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Distal intestinal obstruction syndrome'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Intussusception occurs in approximately 1 percent of patients with CF and may be related to inadequate PERT, causing inspissated bowel contents serving as the lead point. Clinically, it is characterized by colicky abdominal pain, vomiting, a palpable mass, and rectal bleeding. The diagnosis can be made with ultrasound or with a contrast enema, which may also be therapeutic. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Intussusception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CF are susceptible to small intestine bacterial overgrowth (SIBO) primarily because of decreased intestinal motility. Clinical symptoms are nonspecific and include bloating, flatulence, abdominal pain, watery diarrhea, dyspepsia, and weight loss or failure to gain weight. Diagnostic options include hydrogen breath testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      empiric trials of antibiotics. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Small intestine bacterial overgrowth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rectal prolapse occurs in approximately 20 percent of patients with CF and is particularly common in toddlers. It may be associated with constipation, diarrhea, malnutrition, and insufficient PERT dosing. Rectal prolapse should be manually reduced to avoid bowel edema; surgery is rarely necessary. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Rectal prolapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5203268\">",
"    <span class=\"h2\">",
"     Pancreas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancreatic insufficiency affects approximately 85 percent of patients with CF and may cause fat malabsorption with steatorrhea, growth failure, and fat-soluble vitamin deficiencies. The diagnosis and management of pancreatic insufficiency in this population, including strategies for pancreatic enzyme replacement, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29095?source=see_link\">",
"       \"Cystic fibrosis: Assessment and management of pancreatic insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatitis develops in about 10 percent of CF patients with pancreatic sufficiency and is rare among those with pancreatic insufficiency. Among patients with pancreatic sufficiency at the time of the first episode of pancreatitis, about 20 percent subsequently experience a decline of pancreatic function and become pancreatic insufficient. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with exocrine pancreatic insufficiency also develop endocrine pancreatic dysfunction, which ultimately progresses to cystic fibrosis related diabetes (CFRD). The risk of developing CFRD increases with advancing age, the presence of pancreatic insufficiency, the delta F508 homozygous genotype, and female gender. Annual screening for CFRD is recommended and is discussed in a separate topic review. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'CF-related diabetes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5203398\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are multiple presentations of liver disease in CF (",
"      <a class=\"graphic graphic_table graphicRef81636 \" href=\"UTD.htm?1/9/1179\">",
"       table 2",
"      </a>",
"      ), the most common of which are asymptomatic elevation in liver enzyme tests and hepatosplenomegaly. A subset of patients develops cirrhosis, which may progress to end-stage liver disease. Other presentations include cholecystitis and choledocholithiasis. Patients with advanced liver disease may develop portal hypertension, with risks for variceal hemorrhage, nutritional deficiencies, and hepatic synthetic dysfunction. The evaluation includes laboratory testing to evaluate hepatic function and exclude other causes of liver disease, and abdominal ultrasound to detect portal hypertension and gallstones. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Hepatobiliary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CF-related liver disease, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      (UCDA) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); doses of 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      have improved laboratory parameters in small randomized trials. There is insufficient data to determine whether UCDA should be administered to patients with early liver disease. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/1\">",
"      Eggermont E, De Boeck K. Small-intestinal abnormalities in cystic fibrosis patients. Eur J Pediatr 1991; 150:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/2\">",
"      Colombo C, Battezzati PM. Hepatobiliary manifestations of cystic fibrosis. Eur J Gastroenterol Hepatol 1996; 8:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/3\">",
"      Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 2006; 131:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/4\">",
"      Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007; 13:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/5\">",
"      Nousia-Arvanitakis S, Fotoulaki M, Economou H, et al. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001; 32:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/6\">",
"      Bass S, Connon JJ, Ho CS. Biliary tree in cystic fibrosis. Biliary tract abnormalities in cystic fibrosis demonstrated by endoscopic retrograde cholangiography. Gastroenterology 1983; 84:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/7\">",
"      Hebra A, Hoffman MA. Gastroesophageal reflux in children. Pediatr Clin North Am 1993; 40:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/8\">",
"      Malfroot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. Arch Dis Child 1991; 66:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/9\">",
"      Milla PJ. Cystic fibrosis: present and future. Digestion 1998; 59:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/10\">",
"      Eggermont E. Gastrointestinal manifestations in cystic fibrosis. Eur J Gastroenterol Hepatol 1996; 8:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/11\">",
"      Scott RB, O'Loughlin EV, Gall DG. Gastroesophageal reflux in patients with cystic fibrosis. J Pediatr 1985; 106:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/12\">",
"      Bendig DW, Seilheimer DK, Wagner ML, et al. Complications of gastroesophageal reflux in patients with cystic fibrosis. J Pediatr 1982; 100:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/13\">",
"      Ledson MJ, Tran J, Walshaw MJ. Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. J R Soc Med 1998; 91:7.",
"     </a>",
"    </li>",
"    <li>",
"     Ferry, G, Klish, WJ, Borowitz, D, et al. Consensus Conference: Gastrointestinal Problems in Cystic Fibrosis. In: Clinical Practice Guidelines for Cystic Fibrosis, vol II, Cystic Fibrosis Foundation, Bethesda, MD, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/15\">",
"      Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117:e817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/16\">",
"      Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/17\">",
"      van der Doef HP, Arets HG, Froeling SP, et al. Gastric acid inhibition for fat malabsorption or gastroesophageal reflux disease in cystic fibrosis: longitudinal effect on bacterial colonization and pulmonary function. J Pediatr 2009; 155:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/18\">",
"      Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic fibrosis. J Pediatr Surg 2007; 42:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/19\">",
"      Littlewood JM. Cystic fibrosis: gastrointestinal complications. Br Med Bull 1992; 48:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/20\">",
"      Fakhoury K, Durie PR, Levison H, Canny GJ. Meconium ileus in the absence of cystic fibrosis. Arch Dis Child 1992; 67:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/21\">",
"      Gorter RR, Karimi A, Sleeboom C, et al. Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis. J Pediatr Gastroenterol Nutr 2010; 50:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/22\">",
"      Noblett HR. Treatment of uncomplicated meconium ileus by Gastrografin enema: a preliminary report. J Pediatr Surg 1969; 4:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/23\">",
"      Rowe CR. An atlas of anatomy and treatment of midclavicular fractures. Clin Orthop Relat Res 1968; 58:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/24\">",
"      Rescorla FJ, Grosfeld JL. Contemporary management of meconium ileus. World J Surg 1993; 17:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/25\">",
"      Del Pin CA, Czyrko C, Ziegler MM, et al. Management and survival of meconium ileus. A 30-year review. Ann Surg 1992; 215:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/26\">",
"      Ein SH, Shandling B, Reilly BJ, Stephens CA. Bowel perforation with nonoperative treatment of meconium ileus. J Pediatr Surg 1987; 22:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/27\">",
"      Kao SC, Franken EA Jr. Nonoperative treatment of simple meconium ileus: a survey of the Society for Pediatric Radiology. Pediatr Radiol 1995; 25:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/28\">",
"      Caniano DA, Beaver BL. Meconium ileus: a fifteen-year experience with forty-two neonates. Surgery 1987; 102:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/29\">",
"      Karimi A, Gorter RR, Sleeboom C, et al. Issues in the management of simple and complex meconium ileus. Pediatr Surg Int 2011; 27:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/30\">",
"      Khoshoo V, Udall JN Jr. Meconium ileus equivalent in children and adults. Am J Gastroenterol 1994; 89:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/31\">",
"      Houwen RH, van der Doef HP, Sermet I, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr 2010; 50:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/32\">",
"      Dray X, Bienvenu T, Desmazes-Dufeu N, et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2004; 2:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/33\">",
"      Lin LY, Wong JU. Images in clinical medicine. Meconium-like ileus in cystic fibrosis. N Engl J Med 2012; 366:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/34\">",
"      Colombo C, Ellemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011; 10 Suppl 2:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/35\">",
"      Parmley RR, Gendler SJ. Cystic fibrosis mice lacking Muc1 have reduced amounts of intestinal mucus. J Clin Invest 1998; 102:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/36\">",
"      Gy&ouml;m&ouml;rey K, Rozmahel R, Bear CE. Amelioration of intestinal disease severity in cystic fibrosis mice is associated with improved chloride secretory capacity. Pediatr Res 2000; 48:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/37\">",
"      Mailleau C, Paul A, Colin M, et al. Glycoconjugate metabolism in a cystic fibrosis knockout mouse model. Mol Genet Metab 2001; 72:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/38\">",
"      McCabe, AJ, Irish, MS, Borowitz, DS, Glick, PL. The surgical aspects of gastrointestinal disease in cystic fibrosis. New Insights into Cystic Fibrosis 1999; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/39\">",
"      O'Halloran SM, Gilbert J, McKendrick OM, et al. Gastrografin in acute meconium ileus equivalent. Arch Dis Child 1986; 61:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/40\">",
"      Speck K, Charles A. Distal intestinal obstructive syndrome in adults with cystic fibrosis: a surgical perspective. Arch Surg 2008; 143:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/41\">",
"      Holmes M, Murphy V, Taylor M, Denham B. Intussusception in cystic fibrosis. Arch Dis Child 1991; 66:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/42\">",
"      Holsclaw DS, Rocmans C, Shwachman H. Intussusception in patients with cystic fibrosis. Pediatrics 1971; 48:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/43\">",
"      Coughlin JP, Gauderer MW, Stern RC, et al. The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg 1990; 25:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/44\">",
"      McCarthy VP, Mischler EH, Hubbard VS, et al. Appendiceal abscess in cystic fibrosis. A diagnostic challenge. Gastroenterology 1984; 86:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/45\">",
"      Fridge JL, Conrad C, Gerson L, et al. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 2007; 44:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/46\">",
"      Lewindon PJ, Robb TA, Moore DJ, et al. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998; 34:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/47\">",
"      De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293:G104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/48\">",
"      Schneider AR, Klueber S, Posselt HG, et al. Application of the glucose hydrogen breath test for the detection of bacterial overgrowth in patients with cystic fibrosis--a reliable method? Dig Dis Sci 2009; 54:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/49\">",
"      Gregory PC. Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. J Pediatr Gastroenterol Nutr 1996; 23:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/50\">",
"      KULCZYCKI LL, SHWACHMAN H. Studies in cystic fibrosis of the pancreas; occurrence of rectal prolapse. N Engl J Med 1958; 259:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/51\">",
"      Stern RC, Izant RJ Jr, Boat TF, et al. Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology 1982; 82:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/52\">",
"      Nousia-Arvanitakis S. Cystic fibrosis and the pancreas: recent scientific advances. J Clin Gastroenterol 1999; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/53\">",
"      De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics 2005; 115:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/54\">",
"      Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/55\">",
"      Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/56\">",
"      Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/57\">",
"      Bismuth E, Laborde K, Taupin P, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008; 152:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/58\">",
"      Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998; 133:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/59\">",
"      Lanng S, Hansen A, Thorsteinsson B, et al. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995; 311:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/60\">",
"      Lanng S. Glucose intolerance in cystic fibrosis patients. Paediatr Respir Rev 2001; 2:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/61\">",
"      Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/62\">",
"      Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994; 43:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/63\">",
"      O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009; 10 Suppl 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/64\">",
"      Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/65\">",
"      Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999; 28 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/66\">",
"      Williams SG, Westaby D, Tanner MS, Mowat AP. Liver and biliary problems in cystic fibrosis. Br Med Bull 1992; 48:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/67\">",
"      Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/68\">",
"      Melzi ML, Kelly DA, Colombo C, et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int 2006; 19:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/69\">",
"      Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/70\">",
"      Greenholz SK, Krishnadasan B, Marr C, Cannon R. Biliary obstruction in infants with cystic fibrosis requiring Kasai portoenterostomy. J Pediatr Surg 1997; 32:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/71\">",
"      Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996; 75:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/72\">",
"      Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/73\">",
"      Kappler M, Espach C, Schweiger-Kabesch A, et al. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study. Aliment Pharmacol Ther 2012; 36:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/74\">",
"      Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2012; 10:CD000222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/75\">",
"      Siano M, De Gregorio F, Boggia B, et al. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig Liver Dis 2010; 42:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/76\">",
"      Colombo C, Bertolini E, Assaisso ML, et al. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993; 82:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/77\">",
"      Fridell JA, Bond GJ, Mazariegos GV, et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003; 38:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/15/19706/abstract/78\">",
"      Faro A, Shepherd R, Huddleston CB, et al. Lower incidence of bronchiolitis obliterans in pediatric liver-lung transplant recipients with cystic fibrosis. Transplantation 2007; 83:1435.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5858 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19706=[""].join("\n");
var outline_f19_15_19706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5203077\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CATEGORIES OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pancreatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hepatobiliary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GASTROESOPHAGEAL REFLUX DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11986089\">",
"      MECONIUM ILEUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISTAL INTESTINAL OBSTRUCTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTUSSUSCEPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7111548\">",
"      APPENDICEAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SMALL INTESTINE BACTERIAL OVERGROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECTAL PROLAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PANCREATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pancreatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CF-related diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HEPATOBILIARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5203077\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5203223\">",
"      Intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5203268\">",
"      Pancreas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5203398\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/15/14589\" title=\"table 1\">",
"      Diff dx GERD in CF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/9/1179\" title=\"table 2\">",
"      Presentation liver disease CF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42727?source=related_link\">",
"      Causes of chronic pancreatitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29095?source=related_link\">",
"      Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=related_link\">",
"      Cystic fibrosis: Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20536?source=related_link\">",
"      ERCP for biliary disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/48/32519?source=related_link\">",
"      Overview of rectal prolapse in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=related_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_15_19707="Anthrax vaccine recs";
var content_f19_15_19707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended preexposure and postexposure vaccination schedules for anthrax vaccine absorbed",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of prophylaxis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schedule",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preexposure",
"       </td>",
"       <td>",
"        <p>",
"         5 doses (0 wks, 4 wks, 6 mos, 12 mos, and 18 mos)",
"        </p>",
"        <p>",
"         Annual booster to maintain immunity",
"        </p>",
"       </td>",
"       <td>",
"        Intramuscular",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postexposure*",
"       </td>",
"       <td>",
"        3 doses (0, 2, and 4 wks)&bull;&Delta;",
"       </td>",
"       <td>",
"        Subcutaneous",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For previously unvaccinated persons.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      In conjunction with 60-day antimicrobial postexposure prophylaxis.",
"      <br>",
"       &Delta; Administered under an Investigational New Drug (IND) protocol or an Emergency Use Authorization (EUA).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6):1-36.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19707=[""].join("\n");
var outline_f19_15_19707=null;
var title_f19_15_19708="Types of proarrhythmia of antiarrhythmic drugs";
var content_f19_15_19708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of proarrhythmia during treatment with antiarrhythmic drugs (AADs) for atrial fibrillation or flutter according to the Vaughan Williams Classification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventricular proarrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Torsade de pointes (Vaughan Williams class IA and type III drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Sustained monomorphic ventricular tachycardia (usually class IC drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Sustained polymorphic ventricular tachycardia/ventricular fibrillation without long QT interval (class IA, IC, and III drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Atrial proarrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Provocation of recurrence (probably class IA, IC, and III drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Conversion of atrial fibrillation (AF) to flutter (usually class IC drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Increase of defibrillation threshold (a potential problem with class IC drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormalities of conduction or impulse formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Accelerate ventricular rate during AF (class IA and type IC drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Accelerate conduction over accessory pathway (digoxin, type IV drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Sinus node dysfunction, atrioventricular block (almost all drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vaughan Williams classification of AADs used for the treatment of atrial fibrillation or flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class IA",
"        </strong>",
"        - Disopyramide, procainamide, quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class IC",
"        </strong>",
"        - Flecainide, propafenone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class III",
"        </strong>",
"        - Amiodarone, dofetilide, ibutilide, sotalol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class IV",
"        </strong>",
"        - Nondihydropyridine calcium channel blockers (diltiazem and verapamil)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149. .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19708=[""].join("\n");
var outline_f19_15_19708=null;
var title_f19_15_19709="Diff dx acute pelvic pain";
var content_f19_15_19709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acute pelvic pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Gastrointestinal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Appendicitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bowel obstruction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Constipation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diverticulitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fecal impaction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gastroenteritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hirschsprung's disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Incarcerated hernia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intussusception",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Irritable bowel syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Meckel's diverticulitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neoplasm",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Perforated viscous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Regional ileitis (Crohn's disease)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ulcerative colitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Volvulus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Urologic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cystitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neoplasm",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urethritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pyelonephritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Calculi",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Musculoskeletal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abdominal wall hematoma or infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trauma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herniated disc",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Arthritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Strain or sprain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hernia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neoplasm",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Gynecological",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pregnancy complications",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abortion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dysmenorrhea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ectopic pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pelvic inflammatory disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endometritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neoplasm",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ovarian cyst",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salpingitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Torsion of adnexa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rupture of ovarian cyst",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endometriosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Vascular",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ischemic bowel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neoplasm",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sickle cell crisis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neurological",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abdominal epilepsy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abdominal migraine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Depression",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herpes zoster",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neoplasm",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Other",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pneumonia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herniated disk",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Howard, FM. Acute Abdominal Pain. In: Primary Care for Women., Leppert, PC, Peipert, P (Eds), Lippincott, Williams and Wilkins 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19709=[""].join("\n");
var outline_f19_15_19709=null;
var title_f19_15_19710="Antidepressants for treatment of generalized anxiety disorder";
var content_f19_15_19710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F77409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F77409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antidepressants used in treatment of adults with generalized anxiety disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antidepressant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available (US)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected drug interactions and metabolic effects*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoxetine",
"       </td>",
"       <td>",
"        Yes (capsule, tablet, oral solution)",
"       </td>",
"       <td>",
"        Concurrent use with tamoxifen, pimozide or thioridazine is contraindicated. Fluoxetine is a potent inhibitor and substrate of CYP-2D6 as well as a moderate inhibitor of 2C9, 2C19 and 3A4. Interactions include amiodarone, atomoxetine, digoxin, clozapine, codeine, warfarin and phenytoin.",
"       </td>",
"       <td>",
"        No discontinuation symptoms due to long half-life (tapering is not necessary).",
"       </td>",
"       <td>",
"        Activating. Significant drug interactions. Prolonged half-life and active metabolites require weeks to reach steady-state, prolonging time necessary to evaluate effect of dose adjustment and complicating wash-out and withdrawal.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        <p>",
"         Yes (tablet)",
"        </p>",
"        <p>",
"         No (controlled release capsule)",
"        </p>",
"       </td>",
"       <td>",
"        Concurrent use with pimozide, thioridazine, alosetron, ramelteon or tizanidine is contraindicated. Fluvoxamine is a potent inhibitor of CYP-1A2 and 2C19 and moderate inhibitor of 2B6, 2C9, 3A4 and 2D6. It may interact with CYP substrates including clozapine, metoprolol, propranolol, methadone, theophylline and warfarin. Fluvoxamine is a substrate of CYP-1A2 and 2D6.",
"       </td>",
"       <td>",
"        Low risk of insomnia.",
"       </td>",
"       <td>",
"        Significant drug interactions. Short half-life associated with discontinuation symptoms in absence of tapering.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Paroxetine",
"       </td>",
"       <td>",
"        <p>",
"         Yes (tablet, extended release tablet, oral solution)",
"        </p>",
"        <p>",
"         No (paroxetine mesylate tablet)",
"        </p>",
"       </td>",
"       <td>",
"        Concurrent use with tamoxifen, thioridazine or pimozide is contraindicated. Paroxetine is a potent inhibitor of CYP-2D6 and 2B6 and substrate of 2D6. Interactions include amiodarone, atomoxetine, desipramine and propranolol.",
"       </td>",
"       <td>",
"        Low risk of insomnia. Moderate half-life with no active metabolites.",
"       </td>",
"       <td>",
"        Weakly anticholinergic. May cause constipation, dry mouth or drowsiness. Associated with more severe discontinuation symptoms in absence of tapering.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sertraline",
"       </td>",
"       <td>",
"        Yes (tablet, oral solution concentrate)",
"       </td>",
"       <td>",
"        Concurrent use with thioridazine or pimozide is contraindicated. Sertraline is a potent inhibitor of CYP-2D6 only at doses &ge;200 mg daily.",
"       </td>",
"       <td>",
"        Few significant drug interactions. Intermediate half-life.",
"       </td>",
"       <td>",
"        More frequent gastrointestinal symptoms including diarrhea. Oral solution contains alcohol. Discontinuation symptoms may occur absent tapering.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Citalopram",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Citalopram: Yes (tablet, oral solution)",
"        </p>",
"       </td>",
"       <td>",
"        Diverse transformations include CYP-2C19, 2D6&nbsp;and 3A4 metabolism.&nbsp;Moderate inhibitor of CYP-2D6 at high doses.",
"       </td>",
"       <td>",
"        Few significant drug interactions. Low risk of insomnia.",
"       </td>",
"       <td>",
"        <p>",
"         Possible elevated risk of cardiac arrhythmia in combination with other agents that&nbsp;cause QTc prolongation and/or increased citalopram concentrations.",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        Mild discontinuation symptoms may occur absent tapering.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Escitalopram",
"       </td>",
"       <td>",
"        Escitalopram: Yes (tablet)",
"       </td>",
"       <td>",
"        Diverse transformations include CYP-2C19, 2D6&nbsp;and 3A4 metabolism.&nbsp;Moderate inhibitor of CYP-2D6 at high doses.",
"       </td>",
"       <td>",
"        Few significant drug interactions. Low risk of insomnia.",
"       </td>",
"       <td>",
"        Mild discontinuation symptoms may occur absent tapering.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Venlafaxine",
"        </p>",
"        <p>",
"         Desvenlafaxine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Venlafaxine: Yes (extended release tablet and capsule, immediate release tablet)",
"        </p>",
"        <p>",
"         Desvenlafaxine: No (extended release tablet)",
"        </p>",
"       </td>",
"       <td>",
"        Metabolism of venlafaxine includes CYP-2D6 transformation to an active metabolite. Applies to both: no known potent effects on CYP. Can antagonize efficacy of antihypertensive drugs.",
"       </td>",
"       <td>",
"        Few significant drug interactions.",
"       </td>",
"       <td>",
"        Activating. Associated with discontinuation symptoms absent tapering. Dose-related elevation in blood pressure. Gastrointestinal symptoms (eg, nausea) may be more prominent with immediate release form.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nefazodone",
"       </td>",
"       <td>",
"        Yes (tablet)",
"       </td>",
"       <td>",
"        Nefazodone is a potent inhibitor of CYP-3A4 and inducer of P-glycoprotein. Nefazodone is contraindicated in combination with numerous drugs including: carbamazepine, cisapride, dronedarone, dabigatran, pimozide or ranolazine. Nefazodone can increase concentrations of drugs metabolized by 3A4 including simvastatin, cyclosporine, everolimus and tacrolimus, necessitating additional monitoring and dose adjustment. A 50 to 75 percent dose reduction of alprazolam or triazolam is suggested if used with nefazodone. Metabolism of nefazodone includes CYP-3A4 and 2D6 transformations and active metabolites.",
"       </td>",
"       <td>",
"        Sedating. Low risk of insomnia and sexual dysfunction. May be taken at bedtime.",
"       </td>",
"       <td>",
"        Not a first-line choice. Numerous drug interactions due to potent CYP-3A4 inhibition. Rare reports of fatal hepatotoxicity leading to market withdrawal in EU, Canada and elsewhere.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Duloxetine",
"       </td>",
"       <td>",
"        No (delayed release capsule)",
"       </td>",
"       <td>",
"        Duloxetine is a moderate inhibitor of CYP-2D6 and primarily metabolized by 1A2 and 2D6. Can antagonize efficacy of tamoxifen and concurrent use is not recommended. Contraindicated with thioridazine.",
"       </td>",
"       <td>",
"        Sedating. Low risk of insomnia. Useful for comorbid painful conditions such as diabetic neuropathy or chronic pain.",
"       </td>",
"       <td>",
"        Moderate risk of drug interactions particularly with potent inhibitors of CYP-2D6 and/or 1A2.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mirtazapine",
"       </td>",
"       <td>",
"        Yes (tablet, orally dispersible tablet)",
"       </td>",
"       <td>",
"        Diverse metabolic transformations with weak effects on CYP.",
"       </td>",
"       <td>",
"        Sedating. Low risk of insomnia and sexual dysfunction. Useful for patients who may benefit from increased appetite.",
"       </td>",
"       <td>",
"        Drowsiness, increased appetite and weight gain are disadvantageous in most patients. Rare reports of agranulocytosis.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nortriptyline (and other TCAs)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        TCAs are inhibitors of several CYP enzymes and glucuronidation. Nortriptyline is an inhibitor of CYP-D6 and 2C19 and metabolized by 2D6. Concurrent use with pimozide, thioridazine, ziprasidone or other agents known to prolong the QTc interval or associated with cardiac conduction abnormalities or arrhythmias may be regarded as contraindicated.",
"       </td>",
"       <td>",
"        Nortriptyline is sedating. May be taken at bedtime.",
"       </td>",
"       <td>",
"        Not a first-line choice. Potentially cardiotoxic, can cause orthostatic hypotension and decrease seizure threshold. Significant anticholinergic effects include dry mouth, constipation, urinary retention or altered vision. Significant drug interactions.&loz;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TCA: tricyclic antidepressant; SSRI: selective serotonin reuptake inhibitor; CYP: cytochrome P-450.",
"     <br>",
"      * Applies to all: avoid use with monoamine oxidase inhibitors (MAOI). May lower convulsive threshold thereby antagonizing efficacy of anti-epileptic drugs. Applies to all serotoninergic agents: may elevate risk of gastroduodenal bleeding in combination with non-steroidal antiinflammatory drugs or anticoagulants. For additional information refer to topics on NSAIDs and gastroduodenal toxicity. For additional information on drug interactions see Lexi-Interact&trade; drug interaction application or Lexi-Comp drug information topic, Drug Interactions section.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Additional information on adverse effects are listed in the table \"Adverse effects of antidepressants\".",
"       <br>",
"        &Delta; Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. Refer to topics on&nbsp;unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs).",
"        <br>",
"         &loz; For additional information refer to topics on tricyclic and tetracyclic drugs for treating depression.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19710=[""].join("\n");
var outline_f19_15_19710=null;
var title_f19_15_19711="Ultrasound megaureter";
var content_f19_15_19711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound imaging of a megaureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 354px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFiAWIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5oooooAKKKKACiiigAooooAKKKKACiiloA1vC9np1/rEcGs3psrQqxMoHfHAz0H1qvq2mT6dL86SG3Y5imZCokXsfbI7Vp6FoszxpeTRgRn/Vhj198eldXbl7m5S1mdWBUoVk5DAjH8qAPMqWu/1fwxZPdyRFJLa5J+Uw4Mf4r/gRj0rn7/wnqVrE0saJcxKQpMRyRxnoefbNAHP0U+SN4nKSoyOOqsMEUygAooooAKKKKACiiigAooooAKKKKACiitHTNF1HU2AsbSWUH+ILhfz6UAZ9SW0ay3EUbsVVmALAbiB9O9dZZ+EI7e6A1u9VI1PzRWzBnOD03fdHGeefpWrbXenaOWGkWsUbKDiaZBJIc8fePQ8dgKAOZ8aaHb6HqccVlPNcWskSukkke3JI5A9ex/HHasCuq1m6OpAi5y7k5DnqDXLyI0bFWHIoAZRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUqqXYKgLMTgADJNACVraDpyXk++4DG2jOWC8FvamadpF1cX7wS206CFsTgoQU9jnoa7ldOgtVBto2SPbzjnb9aAOz0TQre80F9StbiN7hB/x7sM5HpjuaxI7L+1L4QCA28kZyWPBPrWdZy/ZJPOV3RV5VQ2K1rHWbWS9ie+LIQSGMX3iPSgAhsxF51uZfMlOSMjd+INYJuLqzlkWKRgBj5eoOK7C21WGVr6S0nBlxtUHg49xU2p2aCytlaOCaWRMHySN4xzk0Acuslte27JOUL5Em2RAyNgdMEYqHVvDGiyOjraPHlt0ht5NpORkjByo+gAq4llGbNyj7ZSpO0jrz2qQ6bdW+mmaWNgkijDZ/pQBx114NjUL9nvwWJIO9OAPwNUpfB9+rkJLauvY+ZjP4V093JOLUQNENgHDgYNV08z7KzIxJOOD1GKAOYi8Ka3MXEVg7leoDrn+dVF0LVmJC6XfMV64t3OP0r0LTtQmZzDNO8Q65rSN5O0LTR3iFhxh1xkCgDy0eHtZIyNI1Ej/r2f/CopdH1OJsS6deIfRoGH9K9Ejv75hL5SuWflj2H0plzNPfPEbiRmbHAI64oA4G20LU7ksIrKYFRk7xs/9CxV638JatK7q8UcJTGfMlX9MZrppZHtpNpQnP8ACT1p41CRHLJAq+9AGHD4IvWC+bcQKxbbtTL10Vv4A0qGQLeX9wzFd21lEWDnp3z+lVzrdzbOHt2AOd3yjoaxtQ1W6u5pGmdjk569KAO0im8O+H5pDa6PZOxwymUGRkb2ZiSPwNZMvih380QFY0kJ+Veg/CuVa4ZpNuW57n0pkjADkEYP3qANC4uWuNzH5cn8qqZwwIGR6VFuUAbnIJPAFSRhDk4I7ZzQAxzmQKTvIPT0qC8tlkjbbtXaeM9ass/zZU47Dim/L1J3HPHFAGCylSQwwR2ptadxaNPKqQRs9wzBFjRSzOT0AHrWfIjxyNHIrI6EqysMEEdQRQAyiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACp7KGSe5SOE4fOQc4x71HFG8sixxqWdjgAd66vTdL+yR8jEx6mgDS0m/nsIHj8x5WkYmQucl2PUk+tWrW7eK4ZmPyOMEZ4+lGnaVcXUgWNCx9RW3pOl2ygec6s4bmEg5YfXtQBlXFmLi2affhhzsHpVCdZQiLArq56nHX2rq7y0t3Ihsmfy8ZdWHKH61nTB9OuY1hlDwN13DmgDFt7h0ZFK7SARuxjB9auW2qy2jlA/mDbtVjzt+laPlrcSozq0iHJ4AABqlLpMvlziz/AHsgO4oBk4/pQBoWniWIMFu7NXEY/dY4IP8AWt6LxbpkpaO7h3xlfkfGCp9K4N7G5UZuLaUM3Q4xVTZIrYkj2ovcjpQB6FCNOu7eNo0j8xzkjdtJOeKsx2M9hHcO2mJcxOuMhg233wK88iEhct5jBAeCvStG11HVoVWKKaRYwMg+tAHV2Gm6ddWLO8UUEyEr+8yAQefwNIunPbQJJbywSQjOV4IrAttY1C0EkoaN0yd4bB/Gkj8ShUEb28RUjcCRjJ9aANq4lxLuaALvXBSPnH4VjywSXt95UA3Srwqjin2WvLeM5uIkWULw69RU8OoW63IuAsbkkbvmIbPtQBl6lol5bw77rh+gBINYskm6Fkkfa6dMd66LWtVVz8yuQTkZOcVzdy6dXTdu5yOo+tAGS0rrIQDhT3NNkcAEk7qdcBGdtxwOuM1FIgYYDnFACuxwrLg+1BZUCqc7iM1GybBtQHHfnrTsZHbOOpoAlb5WDZ46YoO0jgkH+dQM20qG4HWlIKg5I9QaAFDlfmJz74pcsdnzAnPUUsIBjy3GecGlyAvPBJ4I9aAHQ7o5ldGKujblYcEHPBB9ao6pAzSPOCW3csT1PvVwccl+nanuARx8xx+FAHP0lXL+1MDBlB2N+lU6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigApQMkY60ldFY29s8NpL9l8mVFIZt5bzDnIbB6cccUAafhfSPIDTSuEuG+7uXgD0reitc3SiXDluuOKbaXVq9ssdwwWVRlXHeo1mKTiRGGccHPBoA6RoIbS0WQSlJFfCgHNOsb1JdRSRQkcpXYw/hY/0rjJ72SWfD/e6n0q5Y3bRMSBluq/WgD0EfZopfIhVVeQ4O48MO9V/FulzfYI5FEHkKC6kDkj2rH0mWRmhEgV3DbhuGc/hW1e288mjvJFJMWViHixhRznj0oA4BNQmsmAmXzE/un0rVs9VtGuPNt3aGZ12sucfTmmXunRzQS3DnEoG7GOtcddgRy/IpyfwxQB26alNLct9skec46rjFPNzFPaCIRRBd2GLdW5rj9N1ie0mGNrqvZueKv3GtwzvmS0RT1yp6UAdfd+GzPbW40xVRnUnb5gOTWA9hqVlcRPJu3J/Aw4NV9M1pLdw5ZnVeVzwRW2PFYkkkJPyNHtO45PtzQBlfa41mZr2y3SOSSFOBj6VQu/sUkpYK8Ax8qnsa1hqUF6bcNBEigkMyjJNX5ItNnl3SopHdvQCgDkEi/e5R16ZIzihGy28EhV7CukOkWzo/lxCV8Z3Iap3vh9YwGt2kDnkxt1NAGBdTO37tA2M96gZSqkHJJ6ir19buDnBDDg5FZ0hIGS231PrQBUmADDI49+TTtjfKWHB9KZMwYAqcjpipADsUDOO9ADZCOdoxj360i4JYAYPbNIFw2d3096TksxYn5ecA0AHKgljx0xipB6ZxkZwRTVYlScnBPpTm+UbpNpHagBV27SoGDmpUTYcdvQ1XUhjwFGentTkIJKsxagBZiu4kDvxihF5JLMMcdKRuB1U9ttOlB2gZ/LtQAjAMpDfMCMYrHuYDBJtJyD0Na2WQAE5OOtOj8gwXSXFsJWkTEblyDG2R83HXjIx70AYNFPkQxsVYcimUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVd02ya8lOAdi8n/CgB+m2RmYSSDEfbPetpiUPzZb0p8Qjjh2KBgfw+lQzSElcZHbmgC7uiZMnGcdqglu9vToO9U3bbjA5PUZphHmFScY60AWi5LBic56VetZsAKSME85rJSRgdoPyjpxUnDndnBHXmgDrLO/aJ8oTlSCCOD+ddvo19dan8txcxxhRuXK43H3ryyGXcpPXHpXVaDfymZIyDLDjDIo5oAt67OS8ilY98ZIYj+dcRqALzF259a73UrCCe3leOV4JG+6rjII+tcPqkDhuGDbRjcDQBl5G8sFye+e1AkyORwe1RODvbdjHX601VwM5OPagCyTEYcDAfv7VESpTK8kds9KTgAAkEe1KB+7Khfw9aALUF7NbkNC3TsRWi2vXJjWIxx/N6LWGhJKkDheq0+R8sMjHpQBsDWZAc8qCeQpxn2rTk8TJLGPMJUgYGD0rjXG0ljlm7URvlgHHWgDoZr5br5nJAPeqN3LDKDHGAWxy1Zj5ZiEPtSNuXhD9aAHCJRkMMelNJdRjt2ApoLfl1zQWyxDHkdMUAOchQOopm4HnqOgp74IyaaA3lgYxQA+Mjy/mz60xVBOc5X0pQ2VwQBntQrDbkd/0oAUsUYHAI6AUO5XayH396Dhup3Y9OopoHykk/jQAuSwLKOAaXed5y3y+opufk2qTgc/Wk+ZxuJGB2oAmDA7QcfiKZweAeB3Bpkqk4Y4OBQCRhsggigCK5hEisRjOeDis5gVYhhgitaNgc9qhvIQ43KCXP60AZ1FFFABRRRQAUUUUAFFFFABRRTkQu4VRyaALkOntLZJcpcW5Jk8sw7/AN4vGdxGOnbOa2bB1t4tgAXb1FZ9pEtuSpOQe+O9SmQLLknPHagCa6LhmZeT6iogxfGcg9xSO7KCSc57elRbskYAz14oAkY+h/CkUdgxxTXJbJYhcUqkhcjHNADgCpGCd3vT1l5xgZNRFW4YHn60RsSMHrQBetpD94YHOR710nh66+z3azTA+WwIJFcmjkMFRefWtWC5dFCk5HpQB3Ru1jtJWaIuspOzkcA8Vxd7tVW3E5PT0rV06+DQMLmLzFGMAHBHvVPUUg2s4DFP4Ae1AHMTON5CnAPc0LJgAflzSzKpyvcmoWBV2KZOKAJS2M7u/pTWYYU5P4VETnnGTQMK3BySPyoAmLqGwpOAMml80SgYXp0qBf4jySDihT8xB+WgCyTxzkk96BgAA9T19qh3ttwpPXikMhG3IO71oAkCbPu9+5ppO3k89qD8w3H8qjbPAJ5oAeARw3C0gOCc4ANNPLgdaQ43kNx70APZSMHdketOBI6sMdM1GWI68gcUKcp1G00AJtc5IHIpQxPBxn0FKr87SCPwpSVbBXj8KAHJhfvDce+KaMLkle/TNN+8TzTs8jdhsUAKSrN14HpQp+TAzimk46DJ70AkdvrQA9sD7pxmgcHIwT2ppyQMEZFIpyxY460APGCxLjHtTgMAgHcT2z0pD0B+UknjnpTWGQc8H1zxQBHe2A+xveLNAMSCMw7v3hyCd2MdOMZ96zK2Ni4Bc4H51QvIPKbcvKH07UAVaKWkoAKKKKACiiloAACSAOprStIfLBJHzdyar2kR+9g5H6VbbACsDu9qAJGX5ep9aRmBGOjY6UhZiMZpc7oyQRx60ANBJTj1peDyDg/Skiwy4GKCSgJ2/jQArAFhnke1A3ByAQAKUEbQ3HPGBSYBwRj04oARgdvyr83vTipI5IB9KbuYEk9DSiQxseNw+lAEsYCtySGBqyzqeC+AOlUsuwLBuT6inRnYxLKMdOaANi2lcLtLHI6kelNvLgzLtc/L0Aqgsz4wmcnvULs3VuueDQASbcgY68ZqE8MQc47AU9mBG3v1pqEZOOfegBmSVODjHFIQd2QMY4qQdDTGYtkHn+lAAAyse565FByW+Y4/Cl5wMcY704q2Mn7ooAVFMjMcEEdOajLHPOetPWR0JwAM0mfkIPJPOaAEY4J5PPtTd2AcfnTwq469PWlOAD6+1AEQ4PILGpExu/edKD69aRiSckcUAISf4eVFIoLAggcdMcU4cgZ/Kkxyfmx9aAFHHrSBhuGRgU4gquQaFzntx6igBW5PHSm8ZHWlK5wRkE0gbHIA/KgB+3IJPXsKaSScYx608NuHQAGkLBQMZHPegBQpGT2I59qixgnbz7+tOOWBO4L7UE4xgigBy/Lzg4HrTsF2OeM+gxUJUp1yR1qQsxwWOAe3tQAbgBjIIHrSfK6sHH5ULjdxg89acWVVJXGT2oAypozG+M5B6VHWo8YePaQADzn0rOlQoxB/A0AMooooAK0bG5uIrWe3STEE2C6YHzY6VVtoTIcn7oq10baBQAq/fHoe4p7JgjJ49ajG5SBgD696UOeVxnPagCQOAeeQe5pCfnyowvQ4pq4yF4wf0odiMqNpoAeqruwRj604ncvt65qLcSBgc+tIuBnkZ7igCYLxyMkDqDTNwx93H0HalU7TkHAx0FKHBXJ6j0oAQkHGM4PvSkbV+U856UjMHwAQO9OYBzgA8HrQAivhcPnA6GgOWY+vXBprIxA5qVYy2MZwO9AAr7SQcimtJuOGGV7UsqYHcEHk0xjhABjFAAChb5uCfWhgDkKpH4UEDaN3TrxQgLfxDIPc0AIBggVe0rRtU1i5a20fTrzULhUMjRWkLSsFBALEKCcZIGfcVSJIkAB4PfrXs37LQlfx1rwti3mnQ5xGUODu82HGPfNAHnM/gnxZawSTT+F9diiQZeSTT5lVR6klcCszTtLv9Ume302xury5RTIY7eJpGCjqcKCcD1r2nwBafGKLxvprXEniX7CtwpuDqc8htxDuG/d5hwflz059Oa1vBt3o97+0R4om8OhPsDafc4aP7rPhd5X2LZIoA+c8EfeBBBxjvTWxk4NeheEPANvrOjal4k8Q69BoXh+2uTbee0LTySy9dqxrz0PX9Dg4ueLvhvp9t4K/4Svwl4kj1zSY5/s84a1a3kibA6gnnqOw6jGaAPMQTkZFXr7S9R0+G2mvrG5torlPMgeaFkEy/wB5SR8w9xXpVv8AC7SdI0vT5/Hni2Lw/qGop5lvZCye4ZU6BpCp+X8ePfrjpPjr4cv3b4ceG7Bory9ayNtG0RykhyoDA+mOc0AeD29vNdXUcFvDJNNKwVI41LFmPQADqak1GyutPvZLTULea1uYjtkgmjKOh9Cp5H417f4X+GPh3S/Hem6bH47tJvFNpcxySWAs5FiZlIZoxLnG7APuTxgVm+OvCN74y+OniixtJoLSCB/tF1eTtiO3iWNdzt/n8utAHjp2qF2jmmn5mGeCK9Yg+Gfh7xCk9v4H8bw61rEMbSixnsZLXzwoyRGzHBPtz9QOareCPhvZa94PvvEmteIV0XT9PuPKufMtDKVXjkYbJbJA247/AIUAeZSL82e3rTTk5Xd+NaviOz02y1m6ttE1M6ppq48q7aBofMGAT8jcjBJHPpWaBtAC4b8KAEZtqDHLe3WmM546g55FSAgZI+99KjeTIyQM+goAcCGIJHy0oYgn8iKQD5VGDjrzSnb/AAknHU0AIVQKpHBPXNAOHPzAZ9KM7wdvIHXJo2swyF+6OKAHtjapxn1+tRRybThufTNKhfqw69/SmyLzx+VAAzknKjjHNCupPzdPbvTgAiZJI9hTQVGMAHJ4oAkL7uFXAxxSXt1Pd2UFtI2Ybfd5SnHy5OTz7mmSfN9KTBHQgigDPKMCeDRV7a/90/nRQA1RiM84HpTicL0P161GsmevQ+gp0hHG05FAEoJPJOaQ85IODUIJUfL+VPXHIwQT70ALjcRkU4Bc46n2FITnAjIA/nSDAIycZ9DQA5sYyDkUIQc9OfalU8kDAHvSkEHLEUAIq7iCT8n8qdjH49Ka5BwBxSliEAC5X1oAUDAPGf8ACnllxgEqD14qPBPbrS4+Ugg+2KALEKA43PhR+tWIdizE7ht+lU0fYfmHNTo5yrbQBQB0mk6GNWkVYtuSM/McZpuv+ErrT03GFsCq2l6lLaOroSuD35r0TRvEcWo2cdtPDE0vmAh2PB+tAHjbxSxyFZI2XFI64ByfavVfFfh8XkjyxJiQ5PAwD7ivNLu0a3kdXByOME0AZ5ypAxgGvav2WfNHjXXvILecdCuCmzO7d5kOMY5zXjQG7gnDdhVvSNW1LRLt7jR9QvNPuWQxtLaTtE7KSCVJUgkZA49hQB6boMHxjOu2xtF8YRymYbTefaBD1/j3/Lt9c8V6mp0s/tJ63/Zgj80aNMLsxY2+dtXd079M++c8187y+OPF0qNFL4q16RHXDK2oTEEehG6sWy1TUtLu2udNv7m0uGUo0tvM0bMp6gkHOD3FAHsvgbwvplv8OLjxUPC0/i/VZdQe2WzRn2Wqrn5mRAS3Y8jGCOnftPEw1E/s96tPqnhex8Ps14kqafaWxh/dBkAeVTyGJBGSBwF4r5y0fxPrXh8yPomrX9h52PMFtOyBz74PP402fxJrc6Xwm1nUZFv8G6V7l2+0Y6b+fmx2zQB7N8f/AA7rPjHxFpHiTwpYXer6TqFlGsT2kTS+WwJyGAHy9epwOD6V1Pidx4T8ffCKLXmQG1tGt55GbIjchVzn2JxXzpo3i3xDolo9ro+t6jYW7nLR29w8ak+uAevvVDUtV1PU0t11O/u7tLdSkInmaQRqeoXcflH0oA9msvht4rT47K5029W1TVDd/wBoeUwg8vfvz5nTOOMZznjFd1oV0j/F34oaTBb6fc6pewE2lvfIHiuGWMHy2GRlT356CvnNPGnihdPi09fEWrizjxsi+2SbVwcgAZ7YGPSsufU7+41M6jdXt1Lflg5uXmYylh0beTnPA5oA+hPCGoePJNadrH4b+DfD0tojyPqN5o0tnHCAOT5obPT0z69Oa5mG5lu/2e/GFyxi8y41uORhCCE5dT8oPOPTNea6r4z8T6zaNZ6pr+rXVmcboZrt2Rsf3gTz+NZ8epX0WmSadFf3aadK4ke2EzCJ2HRimcE++KAKOOMyDGelG3OdvA96UHkjOfqKaFxknBx6UANXdgLxjOeaUKNxLDPtSHI6Uqll5yKAFLddwOKU4PAPFIPmJycdqBgNkYP6UAJtKjgd+aF3KM7uT2oywyFznORSHgnOD64NAChsgLk/SnK+1gSCTUZ4+YDJNHzDjk0AOYZU5J3H9KAmxOCM0xmP0P1o8wkfMc0AObIwCCTRkZIHH0prEhQc8+5prjpkgA8mgB28f3moqLP1ooAhBxkDJWpeGQkckVCSF+7SAndnJ/CgC3GSUycA9KaDhhnB7c01WcL0yB0NKzD6GgCQP2H5UrcHjBNR4JBORn3pxAKdDuHegCQZOOcGm7g5IIpu9iwGMEUvduCT7UAO2ZyRTomYLxyKYxCeuaSMjJByvrQBKud2cZz0NLyP4iCajDZJOTtpwXPPIGetAEmQo+fJBpyzEADaNvTNNcKB1GfUVHjBzzj60AXJJyUAU96v6bqctvMksZI2ntWMjbsj+nWpomGDtJDA9qAPadH8V2GraULK9sw0w6NnGapeLNDtdRhEmmacbVY0Ctub7x9fevNdPu3t5w+78O9es+D9fh1LRbyy1FxvK7Ym25Ye1AHj2pWEltO6ujKw/KqOCMDK+teseLtBR7ATurpcheVHAI9a8wuoBHIR1GOvpQBVYkD5l59aSTaeQOPrSkouRnimLjsMCgAOcjjrSKMnI60YBJz1oUheoIPqKAEJxJkDipcq5OeKhyxbIBx+VPBG36e1AB90cde2aOT1xmmsSWHygj0p53ABgOOlACKxQ54zSFuCSePSmhyflx3pzAAHHXtxQAu7IAPf0707Py46AfrUIJ+6wX61J0wCDjrQALyNwbJHalbHLZPTikRQz55A9BTWXdnHAoAVCGXrj3NBIVhgimhiVGSKUAZ3DrQA8ZEn6CmkYYjrTHLKQc8n0pfMxyc5P6UAP46gH6YphfC+pNN3k5IJ47Cl+Uc9SKAD+HPfuM0wAHqQKVVJyc4qMvk46n1oAmQjacDnsTUbHnOM59aXBxgEEe1Rk/P06UAS+WT/ABH8qKTzV/vfrRQBUzijrRnJ6UUAPHBG1iamSRWABxn3qsOOQeaUhcDB57igCbcATkZx+lOWRXJ3cZquDjp1+tPjfAOf5UASo2G+ZuPWnlgCTnnsaj3Bh/snr7UvmKo+U59zQA8nzG64PvThtYnPaoQTuyRkUrAjDcD2FAEyMqn69xSlgWAycVApwcjke4qXaeWLfpQApLbuB8vXFKvIyvPtTdxxjBPvS7ipBUcdyaAHYIb72D14qeJ8jGAPaoFIwWPT0pu8DlQcUAWA5MrYbbW1pmqtaurRFs5rADYPBAzU6MwP8O4d6APbI/Fra1psZ1JPMkgj2LtUY9Oa898S6O0Z8+N8xOcgr0qLw7dssipJt2scYY9K9DudKWbTUjtFSUZy20kqv1oA8TlVUb6d6jf68Gug8S6RLZ3cimMAA9qwGyCBjOOKAG42gsQSelLEPyphDAnI3CncqowSM9scigB7Jxg9e2aZuwpBxuz0oJYjg5+tOKKwBzz7UAJvw3cmmtkdTx6UKQudy4/CkOGI2nn0oAAG5AyPTBpdpZcj5jSM2Cd6/NSq+3GM+9ABnafmXB9RSs44wQQOuKCxY5IAHc0whRJjnB9KAHE73xGf6U/CrkMRn6d6jcqp+SkJU5IJP1oAAfXik3ZOenaowCfmLN+VSM2Ex2oAdxuxuy3b2pG2iM4I61ErBuFNIVIfDIDmgByH0IyPSnPIc7cDPoKYXCcbfm7VG3zZxn1NAE5Y4IwDULEscngd8VGSV4z9aCxbAJzQA4FQ2Rk+mBSPnHPFAO3BNITliaADJ9BRSc+9FAAKM9aSloAKKKKADNKD+X1o4GMEmjJJxnj3oAVmGAFGPxpWUtgg5JpoOM9KFODn0oAkb5QB972pzyZQbeAPWkZg656MO+aRSVG3GfegB0SP94n5at28ReTA5XvVSFSQcHp2q9Yq+5dpORzxQBK9syyYAJ+hqrJuRsHjFdZY2f2lB5jKHHQ1narp8kLkugx6jnNAGDK2SDyD3xSZ6Ede9Sugzgjj1qKQbBgMCfSgAVhu+QHI65p8cpzkDmoVfCkng1KSud3BzQBpW1xllwSD3PavU/hhqca30NtdzyKsjDJY/LXj8LhTjGAa3LPUDCF8kkt9elAHvvjawgvla2FqnlM2En2dfxFeJ+L/AA3LpEzIYiq9QTXX6T4rmaCJbqWUnIG4Nyn0HStnxMG1mKIC4M2Y8l5AAfpQB4a8Csg2j5+/NVnDDjOcV2uv+Fb2xdJRCSr8jHJrmrmyuU3N5DjHU4oAzgcAc/gKTcQnzdPUU+RX6lQD64qJ1blc/lQBIsgCZ5PpmmDg53YoCgKoGfpTZFYDI6UAPJyOBx3NOJ+U7SAM1GjlRlwMU37zlQCB9aAJS5A4xj2pCSVO4Dj060xm3OAOg7UFyp2kbj/KgB6yBT8oGDSYG4gkj8Kjy6uQq/mKYztnLdaAJWGD1Le1NkJaPLdfc00ysT26elNyQME8+lADo3Cg8H60wsxOSeaVT8wJGaMhm7CgBSwbHAHrxTWG3ihh75+lJ1xxQA4EsoXFIx4wBgCk+mcUcUAFCjJpKWgA59aKSigAooooAKKKKACiiigBe9GaSloAO1GSQAelBOccUd6ALFsOT8xB7elbFnDja3OfasiEAcKdxrVsS3BUnPcCgDp7HBjLE/MOK1PsMV1b7vlMv90ZP6VkWYuNu5BuXv24rpNB1cQgrGAkq9tnNAHI6nozRI37sqfQjpWJJYBV3Mw3DpivdbPTIPFdvPtjie4VeQWKkfSvLNc0O50y7mhmU5RugOeKAOOmhCsx6n2qAYDdACfStO4h+c9VzwcVQuYApJycDvQABgvOP61dt5GDKwGAeDXWeF/h1d3XgnUvGGuNLYaFaxH7OxGHvJSdqqgP8O4jLexAzg44+Nz24xQBrfaHg2+WScnPWui0nxBMSqmQ9MDIziuNW6LL84HHQ1PbzssikZ5oA9u8PXyawGiur14nROGVQSfarll4ft7iG4XfLeHdygQLn9M14zY6i9tLvt2dW74OK7rwz42ubF8ABTJwXds0AQ+JfBsMF25W1mhix1IB5rlZvB8vMqRsy54r13VfF4k09Y1nS5Ln5j5Y+Wq92LO60mIacZfOc/P2H4UAeJ3uiXEWflYAd8Vm/wBnTZOUZsele0v4bvJImhlDcngupGR9ayrrwybN8PGeeAScLQB5YbCdUJKED3qubfAzg7u+BXe6po8iEhWQsOwasC7gCZEoIPoOKAOc/iII/GowoJ4etO6gwPlAHsTVBlPIdeO1AEBIzyAfxpCVLdwP5UBCTjp9aCjKNxHFACghc7Tn6imE5OaViCRjpSUAFKDjPH40meMdqKACiikoAWkoooAKKKKACiiigAooooAKKKKACiiigAooooAKeqk9KWIAvhhV1FRRkArjsaAI7aLccg/N6YrYso3jYdMHrVMqq7WXPPcVbh815FZccevGaAOni8wWw+zzqTjlGqTTEbzyQxWReeBWbBOCCknDVs6JqM0DgrFC+OMt1oA3tPkkhnjmspmW7k+8vIrTmltZ0uBdxFpyMHdy2fas+6uZXiV0IVz2HykfjUVjaPGz3V3cOAPu4G40AcbruivCzSbXKn26fWvXPgr8CDqDRa741hkSw4e201xtaX/al7hfRep74HDeq/DT4e2dnbWmraqsV1dMBNAm4SImRkPkcM3p2HUc4I9OdlRGd2CooyWJwAKAPmP9rzxEkNvovhHTwkcKKLuaOMAKoGUjUY6YG7j3Wvm5V+TPfp1xXZfE/V5/FHjvVtYdSFnmIiDDkRr8qA/8BArk5FPGABn1oAQquzkc+xp0bBBhgcnmoH3RnIH4U3e5YBjn1FAGojA4YNj2HWrCTKpAJYH3rNikwCVbGO1OWUMcvgtQBrR3Uu4gSkAehqzFrF7b4MM7/L2DViJcxgfKPm9qjeVgSeBmgDr38aasYwjXcox0yKzr/wAS313EIZ5XYdevNc8s2UIGcjuacJwMBwGoA1F1eWH5csSR1PNUpTc3T78nJ7miKUM+I1GfpWva2rcPIMAetAGbDp90wG9R9WNTHTJAOdpJ9RWvFNHC++fDHsM02S+jkYsIjn1NAGHNo7AZlZVHqKzbmKCI7QTIa1NUu4+fMfPsDWBLcbidi496AI5lAIIAHtUVKTnrSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUtJRQBPBweg+tWQhc8MM+hqlG5Q8cj0qwjcj5tpPTnIoAuKgwF5X61diaZVXBVgD171mpIzMEIHX7wq/DOkLAOuc0Aa9tKJ/kkCo2eGokjuLSdSj7u/BzVAzISPLBCHqvpUiXJchVOCPzoA2I9WugQ8/zKvTd2rbt9faWz2OgEee3WuWtmWR9jgNk/eORivQfhT4Jh8Q+LYY9SvLeLSLRDdXKtKEMqL/AOc49T2GeQcUAeyfDnU5fCPw6uPEGtSTJYzYNlZE4Mmc4YZ5G7rx/CC3PFanir4haRrHgK4bRrwC5vf9F8lmCyxbgdxZc9MAjI4ya8Z+JfjuLxb4kMVlKYtDslMFpEi7QwHV8ds4GBxgADGc1ykEsVtODbwl938LcmgC/eaNphikFxdb51GfkHH41x2qaUkeDEdyn0ruNH0xbu8LyKIkPVCe9bbaGijMLq5H3g6Bhj2oA8YubEGPgYYVkTW8nmEbTXr9/4agupXBlEGOjgZBP9K5e+8L3aTkRjzB/eSgDhvIYH5T17E1Itu6cv0+tdBPokyEkI/wAvB4zVOXT5g+Gz7DFAGaUUplX+b0p6o3l5ZjkdK0RpE8iAmFx6EVfs9JeQiNoyAOuRmgDnI4JpW2qCQa2dN0RiQ0kbmujttISB1IBKgc8Vee7ihi2Qptcf3WyaAMvyLaFAPs+G9SDVW7kGzChs+prSvJ5bjAjlRQB82+sO5kfeUkkBHqKAKM853bdvPrVK+u3ACAnPscUt8ys+Uc8d6oTgSL1A+tAEU8m5Oq5PpVanumw8tzTD7UAJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUoODmkr0Dxl8Kde8J+DdL8TahPp82nah5WwW0jtJH5kZdd4KADgY4J5oA4SKUoT3FWBKjEZBx7itXwD4T1Dxv4ptdC0loEuZ1dhJOzLGgVSxLFQSOmOnUil8ceG73wV4pvtA1OW3mvLTZveAlozvjVxgsAejDt1oAohhHtKk7evXNXoLiLdnOSe+Kx4JT0yA3ar8Ui4w64J7igDQW53MAjDaDn61q292NpZJjkDBFc7EyhyqgD61YiukhUqG57haAOksgkoYxoQx53CmpcXMEheMjKnr3qnY3oaErnB7Zp0kqpnhGB6igDcTWZuJPOwSMMG6VsaTrLRBjbA73HLBsj8jXCQMqyZXcR/dzV+O68tw0WFHcNQB1ylp0mmLszA5cBsf/rro9L1CzktEKymSdRhg6EfrXndtcLPMC7SKncJ0rodL0m/urPUL3RllayslDXMjEBU3HAHPUn2oA0LnUoDM0Fvbwwhj80jZOatAWVw6+VFH5sY5lA3bvwrj5LGQyLJNcqOckZrYfUbWO1VYJWWZBxs45oA1biVxbiUR28TIenl8kVz11LJqN47RYAA52DFQPq1zDL5krhlYYIHWmRajZruZjOHb+7xQAXMJhGJnY+iq1ZE9yIn2QwkN67qf59u1wS7SeXnuadKYA+/ytyepagCjJczHO6P8hmsyeC4dizRkA+pxV2/vFTJiLD6CqL3jTD7zk+44oApzWiRZLNhvQc1lzRkOSCfritSe8SDPQsepxWbc3Xmg/MfyoAqNjPHNNpaSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+vPEe/xF4atvAzEs+o+C7W/sUzybqA7gij1cYBPotfIde9eM/G1hpHjv4Wa3pmoW11HpmkWkV39llWQxjlZY2wThtjMMHnmgCl8Cy3hjwjr3i3Jjur27ttAsHDYy0jq83uCECkH1Brd8c+C4/G37THim2vDcjTrG1ivrsWsZeaSNLaH93GB1diQAPrjNUPi/q3h7TNc8H+G/CmpWNzolrfyarPNbXCSRB5rgkKzKSB5aAjk/dIzWteePdB0v9o3xbdTaqP7C1qwTTzqmnz7vIJt4cSo6Z5VkK5HQnPagCPR/CWg+KtTXQ7j4SeJPC0E+Y7fWA11IYG/haVXXbtOMHJOM9e45rQPCWi+DPCeteJfHunS6xNbaq+jWemxztDHJNHnfIzrzt+VgO3ynIORjorTStX0y9kvPE/xtV/DsW5y2meIJZbudR0EceT8x4z97Hv1rnvD+raR478A6l4P1PXl0nUotWfVtOvtYm+ScMGDJNL2f5mYsepIxQBoalpngbXfgr4g8X6Boc2l6vbXUMDW73jyrbMZIwSmSMqyt/EODkDgCqnhBvBFjoulR2fhi+8a+ILlPMvgsk0KWjE8RKqqdx9+eeQecDffQdJ8O/s4eL9Ps9csNZvzfWzXk9kzPAjeZFtjRzgPgAnIH8RHatOO+vL7wN4Zt/h3488N+G9KtrCNNQtbm5FtcC6wfMdjtLHJ+mSMjPGACn468C6FYeJPh9cWmlXWm2niCeNLvS53fMOHiDLkncMiQjtjHGOg47xromn6Z8VrzR7O3CabHfRwrBvY4Q7cjcST3Peuw+KfirSTa/C/UdM8QDXl0W6c3kjS/wCkylJIjvaNiWUN5TkbuxHWp/E/h3Q9Q+Ix8YHxt4dXw7c3UN2yfa/9Kx8uYxFjg545I2jkgYIoAu2XgLw1P8dNe8PXFkY9EtdP86OMTyZjbZEd4bOTjcx5JHtWVoGjeHPiB4n8jS/Dk2kaVpFvLc3Ytrl7ma8VSAiKCOHPPTJPPOcVtQ+JNEP7QXivUP7Y0/7BNpDRxXQuo/Kkby4htV84JyDwD2Nef/BDxVZ+H/E2q22rXs9jYarZyWhvYyQ1s5PySAjkY55HQkHoKAPRdA0LSNf1QaLL8M9f8MxTBhBqoNxIsbAZHmB1AAOMck9e3UXPCV5p2jfDnxvZatoa3M2kukV+Fu3j+2HzW29B+72jA4znFY9ppeoabcPd+Jvi8X0OMMwOma5JJczD+EKvIz0zjd/UZ3w2vNO1vw74/wBGl1qC3vtVMUkE+r3W0zAOxJZz1bpnjPP1oAu6B4Ysbfwda+JbzwpqniO41OV/smm2zy7LaIMRud0BOT2yOR71W8ZeEbafwRL4m0rw7qXhm7s5hHdafdmRkZCeJEZwD1IGOnsOp1PD2qya94DsfDel+LYdA8Q6JNJET9taGC7iLcESLw2B069CehrC8fiXR/B8lrq3ju+1vWriQA2lpqLT2qRD/npu6nI6cfTvQB0HxQsfBPg+3srYeGDfX1/ZiUO1/KggOMBgMnJzzjjpXiBVyuWZQo969B/aF1yy1HWtCk0e/s76OPTUSRraZZAjZPBKk4PtXk8lwXT5pBxQBsKYguHVWPucVRvWQdMA9grVlzTFl3Atgd81Ek0bYDsxbtQBoLLIFAJXb3qlNcqJCAcD1xSSTy7NqHNVWkOPmABoAjvWD5Ktu+gqlU8pkbPI2+gqvQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeheB/iBYaR4WuvDHinw7Fr+hTXP2yOP7Q1vLBNgKWV1BOMDpx35wSK89ooA9D8bfEK01Xwxb+GPC2gx6B4einN1JCLlp5LibGN7uwzgDHHPQc8ADgYB83ORmoqnWUEAfd+lAFkTbBheTTo2YNubGfSmoUCcv+lRZZifLyR60AbEP/PRgo+lBljLlgvPrWdDcMoCk8dwadIysQASv06UAX2uS3y7gB6iiBQ4yDz3NVIDKGCoNw96vLGAPmO0/XigCeK4aM7Iyc9z0qO5ncyYLFvqaakYDFtytTZMvxsYnsaAISHAJDBQaktmg3bZAGJqKW2fGXU+5Jp9rKsT8AHHqaALN0sCKCIwc9s1WDKn3YkTPfrSXV0zyfKox7DNVfNkORsoAsFlIJG1j3OKzbkYYn19+lPaYqdhDY+tV5JgeFXA9qAITnPXNJSmkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaSigBach7bitMpR1oAmVtoO5s04TA9lGKhL56AD6U2gDTtroqQTjHqKtSXCyDmQY+lZEYTGd+D709ZXHCslAF1boREgENmpPt+05Vvwqopzy2xjVeSbDEKoFAGnNqIlXDIT+NJbyAtkxYFZonwMFR9RT45gWBJP4tigDZeZVXIh/HFZ01wzZO0j6UNcxd2OfqTUEkqEHEmT7A0ARuUkyclT71BTmkYrgmmUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUtJRQAUUUUAFFFFAC0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_15_19711=[""].join("\n");
var outline_f19_15_19711=null;
